<SEC-DOCUMENT>0001628280-22-020806.txt : 20220804
<SEC-HEADER>0001628280-22-020806.hdr.sgml : 20220804
<ACCEPTANCE-DATETIME>20220804060219
ACCESSION NUMBER:		0001628280-22-020806
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20220804
FILED AS OF DATE:		20220804
DATE AS OF CHANGE:		20220804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pharming Group N.V.
		CENTRAL INDEX KEY:			0001828316
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39822
		FILM NUMBER:		221134439

	BUSINESS ADDRESS:	
		STREET 1:		DARWINWEG 24
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			2333 CR
		BUSINESS PHONE:		31 (0)71 5247 400

	MAIL ADDRESS:	
		STREET 1:		DARWINWEG 24
		CITY:			LEIDEN
		STATE:			P7
		ZIP:			2333 CR

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Pharming Group Group N.V.
		DATE OF NAME CHANGE:	20201014
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>h1pr2022.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i24339fffe594441e90a2cc15755d8cb9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">FORM 6-K</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">PURSUANT TO RULE 13a-16 OR 15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For the Month of August 2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commission File Number&#58; 001-39822</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:115%">Pharming Group N.V.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Its Charter)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Darwinweg 24</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2333 CR Leiden</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">The Netherlands</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">           Form 40-F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)&#58;  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#9744;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated August 4, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">EXHIBIT INDEX</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.071%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit No.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharming Group reports financial results for the first half of 2022</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.403%"><tr><td style="width:1.0%"></td><td style="width:27.340%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pharming Group N.V.</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Sijmen de Vries</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sijmen de Vries</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">CEO</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; August 4, 2022</font></div><div id="i24339fffe594441e90a2cc15755d8cb9_4"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:9pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Pharming Group reports financial results for the first half of 2022</font></div><div style="margin-bottom:3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-indent:-18pt"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#9632;</font><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:9.95pt">Total revenues increased 4% in H1 2022 to US$96.8 million, supported  by increases in physicians prescribing and number of patients  </font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-indent:-18pt"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#9632;</font><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:9.95pt">Strong balance sheet and stable cash flow from RUCONEST&#174;  providing for investments in Pharming&#8217;s future growth</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-indent:-18pt"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">&#9632;</font><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%;padding-left:9.95pt">Continued investment in launch preparations for leniolisib&#59; post period milestones include US FDA filing and grant of accelerated assessment in EMA</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-indent:-18pt"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#9632;</font><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:9.95pt">Reduction in minority stake of BioConnection leads to recognized gain of US$ 12.8 million</font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Leiden, The Netherlands, August 4, 2022&#58; </font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pharming Group N.V. (&#8220;Pharming&#8221; or &#8220;the Company&#8221;) (Euronext Amsterdam&#58; PHARM&#47;Nasdaq&#58; PHAR) presents its preliminary (unaudited) financial report for the first six months of 2022 ended June 30, 2022</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Chief Executive Officer, Sijmen de Vries, commented&#58;</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Pharming delivered strong half year results with total revenues up 4% compared to the same period last year. RUCONEST&#174; sales growth was supported by increases in physicians prescribing and number of patients.  For the second quarter of 2022, sales were US$50.1 million bringing the first half year of 2022 to US$96.8 million.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Concerning pipeline development, we continued to advance leniolisib through the regulatory process as we seek marketing authorization in the US, the UK, and the EEA for the treatment of APDS, a rare, complex and progressive primary immunodeficiency. In the US, we filed a New Drug Application with the FDA for the treatment of APDS in adults and adolescents aged 12 or older at the end of July 2022. On August 2, we announced  a new diagnosis code for reporting cases of APDS, which will be added to the International Classification of Diseases, 10</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82, will be effective starting October 1, 2022. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Looking to Europe, the EEA and the UK remain on track for regulatory filings from October this year. On August 1, we announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib in adults and adolescents aged 12 and older.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In our drive to focus on RUCONEST&#174; sales, the launch and commercialization of leniolisib, and the management of our pipeline, we initiated an internal review of our pipeline. As a result of these initial findings, we have taken the strategic decision to discontinue the development of rhC1INH for acute kidney injury and pre-eclampsia. In line with this decision, we will also de-prioritize further development in the large-scale production of rhC1INH through the use of our transgenic cattle herd. The herd will be maintained while we consider strategic options for acute kidney injury (AKI) to gain value from the work done to date. We will continue to progress the ongoing Phase IIb clinical trial in AKI until further notice.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With these decisions, we continue to evolve as a company, and continue to focus our efforts and resources on the most value enhancing initiatives for our stakeholders.&#8221; </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div><font><br></font></div><div style="margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Strategic highlights</font></div><div style="margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the first half of 2022, we continued to execute on our strategic objectives of building a sustainable business by focusing on RUCONEST&#174; sales, the approval, launch and commercialization of leniolisib, and the ongoing development and management of our pipeline.</font></div><div style="margin-top:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The development of our pipeline will be through a combination of internal development projects - including the development of additional indications for leniolisib and OTL-105 as a gene therapy for HAE - and the potential acquisition of new, late-stage assets through in-licensing and M&#38;A opportunities. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">These potential acquisitions will be financed through a combination of positive cash flow from the RUCONEST&#174; business, anticipated future leniolisib businesses, as well as available cash from our strong balance sheet.  If required, Pharming will access additional funding from the capital markets. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Therefore, with the ongoing focus on our strategic objectives we have initiated an internal review of our pipeline. As a result, we are announcing a number of initial changes to the pipeline as detailed below.</font></div><div><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pipeline development</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">leniolisib</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For leniolisib, a three-step approach has been planned for the coming years. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The first step is the anticipated commercial approval and market launch in the US during the first half of  2023, followed by key markets in the European Economic Area (EEA) and the UK in the second half of 2023. The Company will evaluate additional countries and regions and will commercialize the product either directly, or through strategic distribution partnerships. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The second step includes the approval and launch of leniolisib as a treatment of APDS in children as young as one year of age.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The third step is the continued life cycle management of the leniolisib compound into further indications. </font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">US market</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to FDA approval and granting of priority review by the FDA in the US, we remain on track for the commercial approval of leniolisib in the first quarter and market launch early in the second quarter of 2023.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 29, 2022, a New Drug Application (NDA) was submitted to the US FDA for leniolisib, for the treatment of activated phosphoinositide 3-kinase delta (PI3K&#948;) syndrome (APDS) in adults and adolescents aged 12 or older. Aligned with the goals set out in PDUFA VI, Pharming expects a Filing Notification Letter by Day 60, which will include the FDA&#8217;s determination of priority review. </font><font style="color:#6d6d6d;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If priority review is granted, it is expected that the FDA review will be completed within six months of the 60-day filing date.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In anticipation of a positive outcome from the FDA, we continue to grow our US field force and leverage our marketing capabilities for the commercialization of leniolisib.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Finally for the US market, on August 2, 2022, Pharming announced that a new diagnosis code for reporting cases of APDS, will be added to the International Classification of Diseases, 10</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Revision, Clinical Modification (ICD-10-CM) by the US Centers for Disease Control and Prevention (CDC). The diagnosis code, D81.82, will be effective starting October 1, 2022, and will help accurately identify, stratify and triage US patients eligible for APDS treatments and research opportunities.</font></div><div><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">EU and UK markets</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In Europe, we remain on track with anticipated filings of the market authorization applications to both regulatory agencies - the European Medical Agency (EMA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) - in the second half of 2022. Additionally, the MHRA granted Promising Innovative Medicine (PIM) designation to leniolisib for the treatment of APDS.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, on August 1, we announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib in adults and adolescents aged 12 and older.  Pharming plans to submit the MAA for leniolisib to EMA in October 2022.</font></div><div><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Pediatric clinical development</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The studies to support the initial applications in the US, EU, and UK have enrolled patients ages 12 years and older. To expand access to leniolisib for the treatment of pediatric APDS, Pharming has developed a clinical plan to include children as young as one year of age. During the first half of the year, positive decisions were received from EMA and MHRA on the Pediatric Investigation Plan (PIP) for leniolisib as a treatment for APDS in children. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The leniolisib PIP includes two planned, global clinical trials in pediatric patients with APDS aged 4 to 11 with a second study in patients aged 1 to 6. These two studies will support regulatory filings worldwide. Pharming expects to initiate recruitment for this pediatric program for leniolisib in the second half of 2022.</font></div><div style="padding-right:13.5pt"><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTL-105</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2021, Pharming announced a strategic collaboration with Orchard Therapeutics to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE). The program has made significant progress developing the lentiviral vector to enhance C1-inhibitor expression and is now testing in preclinical HAE disease models. We anticipate providing further updates as we move towards preparing an Investigational New Drug (IND) filing.</font></div><div style="padding-right:13.5pt"><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acute Kidney Injury (AKI)</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following an internal review of our pipeline, we have taken the strategic decision to discontinue further development of this therapy. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">While we consider strategic options to gain value from the work done to date, we will de-prioritize further development and investment in the large-scale production of rhC1INH through the use of our transgenic cattle herd. The herd will continue to be maintained to allow all possible outcomes to be explored.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing Phase IIb clinical trial will continue as we evaluate these strategic options.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pre-eclampsia</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Following an internal review of our pipeline, a decision has been made to discontinue further development and investment. This was due to the choices we have made to prioritize the investments to support the sales of RUCONEST&#174; and the commercialization of leniolisib.</font></div><div><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pompe</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The study into the development of a next-generation alpha-glucosidase therapy for the treatment of Pompe disease is ongoing.  We are currently engaged in preclinical studies. If and when results from these preclinical studies become available, we will update the market. </font></div><div style="padding-right:13.5pt"><font><br></font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Operational highlights</font></div><div style="padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RUCONEST&#174;</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RUCONEST&#174; sales were up 4% in the first half of 2022 providing stable cash flow for  Pharming&#8217;s future growth. Total revenues were US$96.8 million compared to US$93.2 million in the first half of 2021. RUCONEST&#174; sales growth was supported by increases in physicians prescribing and number of patients.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The US market represented 97% of total revenues for the first half of the year, while Rest of World (RoW) and Europe represented 3%.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a continued need for safe and reliable acute treatment options for hereditary angioedema (HAE), we remain confident in the ongoing demand for RUCONEST&#174; and continued single digit growth for the 2022 financial year.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Organizational update</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">Robert Friesen, Chief </font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Scientific</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> Officer and Executive Board member resigned from his role at Pharming Group. Mr Friesen&#8217;s succession is currently under review. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Financial Summary </font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:41.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.875%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Amounts in US$m except per share data</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">H1 2022</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">H1 2021</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% Change</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Income Statement</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96.8</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.2</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87.9</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83.8</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating profit</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.6</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.2</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit for the year</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.2</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.4</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &#38; marketable securities</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">190.9</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189.8</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Share Information</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share (US$)</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.029</font></td><td colspan="3" style="border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.022</font></td><td colspan="3" style="border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><font style="color:#595959;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share (US$)</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.027</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #59595B;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.019</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #59595B;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42%</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial highlights </font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">H1 2022</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenues increased by 4% during the first half of 2022 to US$96.8 million, versus US$93.2 million during the first half of 2021. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gross profit increased by 5% during the first half of 2022, in line with the growth in revenues. Gross profit for 2022 was US$87.9 million (2021&#58; US$83.8 million).</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other income increased significantly in 2022 (US$15.0 million) as compared to 2021 (US$1.4 million) as Pharming reduced its minority stake in BioConnection from 43.85% to 22.98% in April 2022.  As a result of this transaction, Pharming has received one-off net cash proceeds of US$7.5 million (EUR6.9 million) and recognized a gain of US$12.8 million.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating profit for the first half of 2022 amounted to US$20.6 million, a 20% increase compared to the same period last year (US$17.2 million). This was mainly driven by the increase in other income of US$13.6 million. This was partly offset by an increase in operating costs resulting from a combination of increased R&#38;D expenditure, launch preparation and manufacturing cost for leniolisib, and an increase in travel related expenses post-COVID.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net profit for H1 2022 was US$19.2 million, a 33% increase compared to H1 2021 (US$14.4 million). This was due to higher operating profit, increased financial income, and a decrease in tax expenses, which was offset by a decrease in the net profits in associates using the equity method.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash and cash equivalents, together with restricted cash, decreased from US$193.0 million at the end of 2021 to US$190.9 million at the end of the second quarter 2022. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Q2 2022</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the second quarter of 2022, revenues increased by 1.0% to US$50.1 million, compared to US$49.7 million in the second quarter of 2021. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Gross profit increased by 2.4%, to US$46.1 million as compared to the same period last year. This was in line with the growth in revenues. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating profit of US$17.8 million was recorded for the second quarter of 2022. This was a 63.3% increase compared to the same quarter last year. This was a result of Pharming recognizing a gain of US$12.8 million in relation to the reduction in its minority stake in BioConnection, partly offset by increased costs for the leniolisib launch preparations. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net profit for the second quarter was US$15.7 million compared to US$5.8 million in the second quarter of 2021. This was mainly due to the one-off recognized gain of US$12.8 million from the reduction in its minority stake in BioConnection.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Outlook</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the remainder of 2022, we expect&#58; </font></div><div style="padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Single digit growth in Group revenues from RUCONEST&#174; sales, driven by the US and expanded EU markets, are subject to potential business restrictions related to the COVID-19 pandemic. Quarterly fluctuations are expected.</font></div><div style="padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">The submission of leniolisib&#8217;s regulatory filings to EMA and UK MHRA are expected in the second half of 2022. </font></div><div style="padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Subject to positive outcomes of the FDA review and granting of a Priority Review for leniolisib, we anticipate commercial approval from the FDA in the first quarter of 2023, with an anticipated launch and commercialization soon after. </font></div><div style="padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Pharming will continue to allocate resources towards the anticipated launch and commercialization of leniolisib with the view of accelerating future growth. Investments in launch preparations and focused clinical development for leniolisib will continue to impact profit for 2022. With continued cash flow from  RUCONEST&#174; funding these investments, no additional financing to support the current business is expected.</font></div><div style="padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Investment and continued focused on the potential acquisitions and in-licensing of new, late-stage development opportunities and assets in rare diseases. Financing, if required, would come via a combination of our strong balance sheet and access to capital markets. </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No further specific financial guidance for 2022 is provided.</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Additional information</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:13.5pt"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Presentation</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The conference call presentation is available on the Pharming.com website from 10&#58;30 CET</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Conference Call</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The conference call will begin at 13&#58;30 CET. A transcript of the call will be made available on the Pharming.com website the following day at 14&#58;30 CET</font><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Please note, the Company will only take questions from dial-in attendees</font><font style="background-color:#ffffff;color:#59595b;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dial-in numbers for conference call</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Netherlands Local&#58; +31 85 888 7233</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United Kingdom Toll-Free&#58; +44 800 640 6441</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United Kingdom Local&#47;International&#58; +44 20 3936 2999</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United States Local&#58; +1 646 664 1960</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">United States Toll Free&#58; +1 855 979 6654</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Access Code&#58; 114487</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Webcast Link&#58; </font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;www.sec.gov&#47;Archives&#47;edgar&#47;data&#47;webcast.openbriefing.com&#47;pharming-q22022&#47; </font><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Calendar 2022</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">H.C. Wainwright Annual Global Conference         September 12 - 14</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third Quarter 2022 Results                                      October 27</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jefferies London Healthcare Conference               November 15 - 17</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stifel Healthcare Conference 2022                         November 15 - 16</font></div><div><font><br></font></div><div style="margin-top:3pt;text-align:justify"><font style="background-color:#ffffff;color:#00497f;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">For further public information, contact&#58;</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Pharming Group N.V., Leiden, The Netherlands</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Heather Robertson, Investor Relations Manager </font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">T&#58; +31 7 1 524 7400</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E&#58; investor&#64;pharming.com</font></div><div style="margin-top:3pt"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">FTI Consulting, London, UK</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Victoria Foster Mitchell&#47;Alex Shaw</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">T&#58; +44 203 727 1000</font></div><div style="padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">LifeSpring Life Sciences Communication, Amsterdam, The Netherlands</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leon Melens</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">T&#58; +31 6 53 81 64 27</font></div><div style="padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">E&#58; pharming&#64;lifespring.nl</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:115%">About Pharming Group N.V. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pharming Group N.V. (Euronext Amsterdam&#58; PHARM&#47;Nasdaq&#58; PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden, Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit the Pharming Corporate website.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt"><font style="background-color:#ffffff;color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Auditor&#8217;s involvement</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Condensed Consolidated Interim Financial Statements have not been audited by the Company&#8217;s statutory auditor.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Responsibility Statement</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Board of Directors of the Company (the &#8220;Board&#8221;) hereby declares that to the best of its knowledge, the condensed interim financial statements, which have been prepared in accordance with IAS 34 (interim financial reporting), give a true and fair view of the assets, liabilities, financial position and profit or loss of the Company, and this interim Board report includes a fair review of the information required pursuant to section 5&#58;25d(8) and (9) of the Dutch Financial Supervision Act (Wet op het financieel toezicht). </font></div><div><font><br></font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leiden, August 4, 2022</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sijmen de Vries, Executive Director and Chief Executive Officer</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Paul Sekhri, Non-Executive Director and Chairman of the Board of Directors</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deborah Jorn, Non-Executive Director</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Steven Baert, Non-Executive Director</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leonard Kruimer, Non-Executive Director</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jabine van der Meijs, Non-Executive Director</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Barbara Yanni, Non-Executive Director</font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark Pykett, Non-Executive Director</font></div><div style="margin-bottom:3pt;padding-right:13.5pt"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt"><font style="background-color:#ffffff;color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-looking Statements </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This press release contains forward-looking statements, including with respect to timing and progress of Pharming&#8217;s preclinical studies and clinical trials of its product candidates, Pharming&#8217;s clinical and commercial prospects, Pharming&#8217;s ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming&#8217;s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming&#8217;s clinical trials and ramifications for the cost thereof&#59; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming&#8217;s 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming&#8217;s actual </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="background-color:#ffffff;color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Inside Information</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.</font></div><div style="margin-bottom:6pt;margin-top:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i24339fffe594441e90a2cc15755d8cb9_7"></div><div style="margin-top:3pt;text-align:justify"><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:115%">Pharming Group N.V.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the period ended 30 June 2022</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Condensed consolidated statement of profit and loss</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Condensed consolidated statement of comprehensive income</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Condensed consolidated balance sheet</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Condensed consolidated statement of changes in equity</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">Condensed consolidated statement of cash flow</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="i24339fffe594441e90a2cc15755d8cb9_10"></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:64.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.030%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the 6-month period ended 30 June</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">notes</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,763</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,237</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs of sales</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,906)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,487)</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,857</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83,750</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,955</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,354</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,296)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,206)</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,421)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,060)</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing and sales</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,449)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,686)</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Operating Costs</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(82,166)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(67,952)</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating profit</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,646</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,152</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value gain (loss) on revaluation derivatives</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other finance income</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other finance expenses</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,780)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,958)</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance gain (cost) net</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,694</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,484</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share of net profits in associates using the equity method</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(550)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">388</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Profit before tax</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,790</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,024</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax credit (expense)</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,587)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,672)</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Profit for the year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,203</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,352</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per share (US$) </font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.029&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.022&#160;</font></td><td style="background-color:#ffffff;border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-left:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share (US$) </font></td><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.027&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.019&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i24339fffe594441e90a2cc15755d8cb9_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the 6-month period ended 30 June</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td><td colspan="3" style="border-left:1.5pt solid #b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Profit for the year</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,203</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,352</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation differences</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,755)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,582)</font></td><td style="border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value remeasurement investments</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Items that may be subsequently reclassified to profit or loss</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,457)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,582)</font></td><td style="border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of tax</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,457)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,582)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss) for the year</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,746</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,770</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div><font><br></font></div><div><font><br></font></div><div id="i24339fffe594441e90a2cc15755d8cb9_16"></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.903%"><tr><td style="width:1.0%"></td><td style="width:57.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEET</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">as at date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">notes</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,766&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,834&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,674&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,284&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,943&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term prepayments</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,594&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,216&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments accounted for using the equity method</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,143&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,201&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity instruments designated as at FVTOCI</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,449&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in debt instruments designated as at FVTPL</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,845&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">136,918</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">147,871</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,929&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,310&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,878&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,983&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,964&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,924&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">256,980</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">249,444</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393,898</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">397,315</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,469&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,429&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share premium</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458,357&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,254&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,607)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253,549)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273,167)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199,670</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192,916</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible bonds</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,235&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,007&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,647&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,456&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financial liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,034</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">157,628</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible bonds</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other payables</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,074&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,473&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="3" style="border-left:2pt solid #D9D9D9;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,194</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,771</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity and liabilities</font></td><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">393,898</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">397,315</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><div id="i24339fffe594441e90a2cc15755d8cb9_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:18.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENT CHANGES IN EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the period ended 30 June</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Attributable&#160;to&#160;owners&#160;of&#160;the&#160;parent</font></div></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.048%"><tr><td style="width:1.0%"></td><td style="width:36.878%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">notes</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares<br>(in '000)</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share capital</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share premium</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal reserve Capitalized development cost</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal reserve FV revaluation</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2021</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">638,822</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,312</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">447,130</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,955</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Result for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax expense from excess tax deductions related to Share-based payments</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonuses settled in shares</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of conversion rights on convertible bonds</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for cash</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised&#47; issued</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,240&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,054&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total transactions with owners, recognized directly in equity</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,301</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,074</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">646,123</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,400</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455,204</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,955</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #bfbfbf;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bfbfbf;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bfbfbf;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bfbfbf;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #bfbfbf;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2022</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">648,749</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,429</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">455,254</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,283)</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Result for the year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(702)</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax expense from excess tax deductions related to Share-based payments</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonuses settled in shares</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for cash</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised&#47; issued</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,103&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total transactions with owners, recognized directly in equity</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,665</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,103</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">652,414</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,469</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">458,357</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">402</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,985)</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><div id="i24339fffe594441e90a2cc15755d8cb9_22"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENT CHANGES IN EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the period ended 30 June</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Attributable&#160;to&#160;owners&#160;of&#160;the&#160;parent</font></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:41.236%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">notes</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal reserve participating interest</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal reserve Translation</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2021</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">622</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,037</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(295,621)</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">183,435</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Result for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,352&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,352&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,582)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,582)</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,582)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,352</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,770</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax expense from excess tax deductions related to Share-based payments</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,794)</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonuses settled in shares</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value of conversion rights on convertible bonds</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for cash</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised&#47; issued</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,028)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,113&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total transactions with owners, recognized directly in equity</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">388</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,683)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,867</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,010</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,455</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(283,952)</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,072</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at January 1, 2022</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,316</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,965</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(273,167)</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">192,916</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Result for the year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,203&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,203&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,755)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,457)</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive income (loss) for the half-year</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(14,755)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,203</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,746</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal reserves</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Tax expense from excess tax deductions related to Share-based payments</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonuses settled in shares</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for cash</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised&#47; issued</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,838)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total transactions with owners, recognized directly in equity</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(550)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</font></td><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">766</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,790)</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(253,549)</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199,670</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><div id="i24339fffe594441e90a2cc15755d8cb9_25"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"></td><td style="width:65.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the 6-month period ended 30 June</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in $&#8217;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Profit before tax</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,790</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,024</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Non-cash adjustments&#58;</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation, amortization, impairment</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,263&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,518&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity settled share-based payments</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,879&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposal of investment in associate</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,708)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value gain (loss) on revaluation of derivatives</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other finance income</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,474)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,398)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other finance expense </font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,958&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net profits in associates using the equity method</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating cash flows before changes in working capital</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,080</font><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,692</font><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Changes in working capital&#58;</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,619)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,150)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade and other receivables</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,895)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,649)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables and other current liabilities</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,601&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,542)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total changes in working capital</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,997)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,317)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest received (paid)</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes paid</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,422)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flows generated from (used in) operating activities</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,607</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,418</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditure for property, plant and equipment</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(729)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,436)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment intangible assets</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(829)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,206)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in associate</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,578&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of license</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,083)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flows generated from (used in) investing activities</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,020</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,725)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment on contingent consideration</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,000)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,594)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds of issued convertible bonds</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interests on loans</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,052)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,261)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds of equity and warrants</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash flows generated from (used in) financing activities</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,340)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,012)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) of cash</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,287</font><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,319)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange rate effects</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,247)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at 1 January</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,924&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,159&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash and cash equivalents at 30 June</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189,964</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">188,303</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div id="i24339fffe594441e90a2cc15755d8cb9_28"></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div><font style="color:#00679b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to the condensed consolidated financial statements </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the period ended 30 June 2022</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Company information</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharming Group N.V. is a limited liability public company which is listed on Euronext Amsterdam (PHARM) and on the NASDAQ (PHAR), with its headquarters and registered office located at&#58;</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Darwinweg 24</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2333 CR Leiden</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Netherlands</font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Statement of compliance</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated interim financial statements for the six-month period ended 30 June 2022 have been prepared in accordance with International Accounting Standard IAS 34, Interim financial reporting.  The condensed interim financial statements should be read in conjunction with the annual financial statements for the year ended 31 December 2021, which have been prepared in accordance with International Financial Reporting Standards (IFRS) and IFRS interpretations committee (IFRS IC) interpretations applicable to companies reporting under IFRS as issued by the International Accounting Standards Board (IASB) and valid as of the balance sheet date. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim financial statements were authorized for issue by the Board of Directors on 3 August 2022.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The published figures in these condensed consolidated financial statements are unaudited.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Accounting policies</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting policies are consistent with those of the financial statements for the year ended 31 December 2021.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Estimates and judgements</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of interim financial statements in conformity with IAS 34 and Book 2 Title 9 of the Dutch Civil Code requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company&#8217;s accounting policies. In preparing these condensed interim financial statements, the significant judgements made by management in applying the Company&#8217;s accounting policies were the same as those applied to the consolidated financial statements for the year ended 31 December 2021.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Going concern</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing and finishing the interim financial statements the Board of Directors of Pharming have assessed the Company&#8217;s ability to fund its operations for a period of at least twelve months after the date the interim financial statements are issued. Based upon the assessment on a going concern basis, the Company has concluded that funding of its operations for a period of twelve months, after the date the interim financial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements are issued, is realistic and achievable. Overall, based on the outcome of this assessment, the interim financial statements have been prepared on a going concern basis.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">6.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Seasonality of operations</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seasonality has no material impact on Company&#8217;s interim financial statements.</font></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">7.</font><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">S</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">egment information</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors consider the business from both a product and  geographic perspective. From a product perspective, the Company&#8217;s business is exclusively related to the recombinant human C1 esterase inhibitor business. From a geographic perspective, the Company is operating in the US, Europe and RoW. The Board of Directors primarily measures revenues and gross profit to assess the performance of the geographic areas. Operating costs as well as non-current assets are not sub-allocated to the geographic areas.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues and gross profit per geographic segment for the period ended 30 June&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.935%"><tr><td style="width:1.0%"></td><td style="width:47.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.749%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #C7C8CA;border-right:2pt solid #C7C8CA;border-top:1.5pt solid #b6b6b6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</font></td><td colspan="3" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,136</font></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #C7C8CA;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,079&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #C7C8CA;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe &#38; RoW</font></td><td colspan="3" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,627</font></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #C7C8CA;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #C7C8CA;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">96,763</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,237</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit&#58;</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #B2B4B6;padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #B2B4B6;border-right:2pt solid #B2B4B6;border-top:2pt solid #B2B4B6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US</font></td><td colspan="3" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,329</font></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,505&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe &#38; RoW</font></td><td colspan="3" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528</font></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total gross profit</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,857</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83,750</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">8.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Other income</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income increased significantly in 2022 (US$15.0 million) as compared to 2021 (US$1.4 million) as Pharming reduced its minority stake in BioConnection from 43.85% to 22.98% in April 2022.  As a result of this transaction, Pharming has recognized a gain of US$12.8 million. The remainder of the increase relates to increased government grants granted on R&#38;D activities.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">9.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.42pt">Expenses by nature</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales in the first half year of 2022 amounted to US$8.9 million (HY 2021&#58; US$9.5 million) and relate to actual product sales. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating costs increased to US$82.2 million compared to US$68.0 million in the first half year of 2021. The increase was a combination of increased R&#38;D expenditure, launch preparation and manufacturing cost for leniolisib, and an increase in travel related expenses post-COVID.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee benefits</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee benefits are charged to research and development costs, general and administrative costs</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or marketing and sales costs based on the nature of the services provided.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization charges</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:55.802%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.448%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment </font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(877)</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,044)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,385)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,251)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,089)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,263)</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,518)</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of depreciation charges of property, plant and equipment and right-of-use assets in 2022 as compared to 2021 stems mainly from favorable currency translation effects.  </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in amortization of the intangible assets mainly relates to amortization of our new ERP system, which is operational as of January 2022. This is partly offset by favorable currency translation effects.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">10.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Financial income (expenses) </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.309%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency results</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,474&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,355&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other financial income</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,474</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,398</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency results</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</font></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on convertible bonds</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,434)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,667)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other interest expenses</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(479)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other financial expenses</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other financial expenses</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,780)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,958)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other financial income and expenses</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,694</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,440</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oreign currency results in the EUR functional currency entities, primarily follow from the revaluation of bank balances and the loan which are denominated in foreign currencies, mainly US dollars. The US dollar strengthened over the course of 2022.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">11.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Investments</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments accounted for using the equity method</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset relates to an investment in the ordinary shares of BioConnection Investments B.V. During the second quarter of 2022, Pharming entered into a share purchase agreement, following receipt of an offer for all shares in BioConnection by Gimv, a European investment company listed on Euronext Brussels. The existing shareholders (including Pharming) reached agreement with Gimv on the sale of all issued and outstanding shares to a new holding company (BioConnection Investments B.V.) incorporated by Gimv, followed by a partial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">re-investment by  existing shareholders of the purchase price in the share capital of BioConnection Investments B.V. The re-investment relates to the purchase of ordinary shares and a preference share.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors made an assessment on the accounting treatment of the agreement and concluded that the sale of the BioConnection ordinary shares and purchase of the BioConnection Investments B.V. ordinary shares shall be considered as a dilution of an existing equity stake in an investment in associate. Hence Pharming recognized the dilution of its equity stake as a reduction of the carrying amount of the investment in associate accounted for using the equity method. The preference share is valued as an investment in debt instruments designated as at fair value with changes through profit and loss (FVTPL). As a result of this transaction, Pharming has received one-off net cash proceeds of US$7.5 million (EUR6.9 million) and recognized a gain of US$12.8 million</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Board of Directors&#8217; judgement, the investment in BioConnection constitutes an investment in an associated company and is therefore not consolidated, as Pharming has significant influence but does not have control of BioConnection and is embargoed by a shareholders agreement between the shareholders of BioConnection from influencing any activity between the two parties which is in any significant way different from the relationship which existed between the two prior to the investment.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of this investment has changed as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.309%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,       2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at 1 January</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,201</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,118</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of financial guarantee</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33)</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilution of equity stake</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,104)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profit (loss) for the period</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(550)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rate movements</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(578)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,143</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,201</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in debt instruments designated as at FVTPL</font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The asset relates to the preference share as obtained as part of the agreement referred to above relating to BioConnection Investments B.V. The Board of Director&#8217;s made an assessment on the accounting treatment of the preference share obtained. The Board concluded that the asset should be recognized as a financial asset (debt instrument) measured at initial recognition at fair value, subsequently measured at fair value through profit and loss. The fair value is calculated using the forward-looking Black-Scholes-Merton (&#8220;BSM&#8221;) financial instrument pricing framework.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of this investment has changed as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.309%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,       2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at 1 January</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,235&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rate movements</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(390)</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,845</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in equity instruments designated as at FVTOCI</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Group holds 1,0 per cent of the ordinary share capital of Orchard Therapeutics, a global gene therapy leader. The share were acquired as of July 1, 2021, as part of strategic collaboration between Pharming Group N.V. and Orchard Therapeutics to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex-vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE), a life-threatening rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors do not consider that the Group is able to exercise significant influence over Orchard Therapeutics as the other 99.0 percent of the ordinary share capital is publicly traded at the Nasdaq stock exchange (Nasdaq&#58; ORTX).</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of this investment has changed as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.309%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,       2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at 1 January</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,449</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Initial recognition</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments through OCI</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702)</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,077)</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</font></td><td style="border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">643</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,449</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">12.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Intangible assets</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in intangible assets mainly stems from regular amortization charges (US$2.3 million) and currency translation effects (US$6.6 million), partly offset by capital expenditures (US$0.8 million).</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">13.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Property, plant and equipment</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in property, plant and equipment mainly stems from regular depreciation charges (US$1.4 million) and currency translation effects (US$0.9 million), partly offset by capital expenditures (US$0.7 million). </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">14.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Right-of-use assets</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in the right of use asset is mainly caused by regular depreciation. No new significant investments for the first half year of 2022.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">15.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Deferred tax assets</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax asset decreased mainly due to offsetting the current tax expense with unused tax losses from prior years.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">16.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Inventories</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories include batches RUCONEST&#174;, work in progress and skimmed milk available for production of RUCONEST&#174;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:58.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,       2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,034</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,560</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress </font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,854</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,606</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,041</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144</font></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</font></td><td colspan="2" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,929</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,310</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the adjustment to net realizable value&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US $ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period to<br>June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period to <br>December 31,<br>2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at 1 January</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,448)</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(646)</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition to impairment</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-2,342</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of impairment</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Usage of impairment</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rate movements</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187</font></td><td colspan="3" style="border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</font></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,386)</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,448)</font></td><td style="border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inventory valuation at June 30, 2022 of US$33.9 million is stated net of an impairment of US$2.4million (2021&#58; US$2.4 million). The impairment includes an impairment for obsolescence and an impairment to write inventories down to their net realizable value. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are available for use in commercial, preclinical and clinical activities. Estimates have been made with respect to the ultimate use or sale of product, taking into account current and expected sales as well as preclinical and clinical programs. These estimates are reflected in the additions to the impairment. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of vials used in preclinical and clinical programs are presented under the research and development costs.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main portion of inventories at June 30, 2022 have expiration dates starting beyond 2023 and are all expected to be sold and&#47;or used before expiration.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">17.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Equity</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s authorized share capital amounts to &#8364;8.8 million and is divided into 880,000,000 ordinary shares with a nominal value of &#8364;0.01 each. All 652,414,282 shares outstanding at June 30, 2022 have been fully paid-up. Other reserves include those reserves related to currency translation, share-based compensation expenses and other equity-settled transactions. </font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to the Condensed Consolidated Statement changes in Equity.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">18.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Convertible bonds</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 21, 2020, the Company issued &#8364;125 million aggregate principal amount of 3.00% convertible bonds</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due 2025.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movements of the convertible bonds were as follows&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.391%"><tr><td style="width:1.0%"></td><td style="width:57.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.444%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts in US$ &#8216;000</font></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period to<br>June 30,<br>2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period to <br>December 31,<br>2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at 1 January</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140,886</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">151,767</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value initial recognition</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid (cash flow)</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,052)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,448)</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization transaction cost</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</font></td><td style="border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,447&#160;</font></td><td style="background-color:#ffffff;border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#59595B;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange rate movements</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7F7F7F;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,305)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#7f7f7f;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,729)</font></td><td style="background-color:#ffffff;border-right:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #b6b6b6;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying value at end of period</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:1.5pt solid #b6b6b6;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,963</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:1.5pt solid #b6b6b6;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">140,886</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1.5pt solid #b6b6b6;border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">19.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Earnings per share and diluted shares</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated based on the weighted average number of ordinary shares outstanding during the year. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding including the dilutive effect of shares to be issued in the future under certain arrangements such as option plans and warrants issued. For HY 2022 and HY2021, the basic and diluted profit (loss) per share is&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:58.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.309%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#376092;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2022</font></td><td colspan="3" style="background-color:#376092;border-right:1.5pt solid #b6b6b6;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">H1 2021</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net profit (loss) attributable to equity owners of the parent (in US $ '000)</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,203&#160;</font></td><td style="background-color:#DCE6F2;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,352&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding (in '000)</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">655,168</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">641,099</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic profit (loss) per share (in US $)</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.029</font></td><td colspan="3" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.022</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average fully-diluted shares outstanding (in '000)</font></td><td colspan="3" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:1.5pt solid #b6b6b6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">718,197</font></td><td colspan="2" style="background-color:#ffffff;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">762,115</font><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fully-diluted profit per share (in US $)</font></td><td colspan="3" style="background-color:#dce6f2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.027</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.019</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><img alt="logo_greyxoriginalx.jpg" src="logo_greyxoriginalx.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diluted shares</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The composition of the number of shares and share rights outstanding as well as authorized share capital as per  June  30, 2022 is provided in the table below&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.230%"><tr><td style="width:1.0%"></td><td style="width:24.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.308%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:0 1pt"></td><td colspan="3" style="background-color:#376092;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</font></td><td colspan="3" style="background-color:#376092;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares issued</font></td><td colspan="3" style="background-color:#376092;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares reserved</font></td><td colspan="3" style="background-color:#376092;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#FFFFFF;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</font></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued shares</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648,749,282&#160;</font></td><td style="background-color:#dce6f2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,664,610&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,413,892&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,789,478&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,542,500)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328,562)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,918,416&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible bonds</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,412,622&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,412,622&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LTIP</font></td><td colspan="2" style="background-color:#dce6f2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,992,546&#160;</font></td><td style="background-color:#dce6f2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,849,504)</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,350,406&#160;</font></td><td style="background-color:#DCE6F2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,493,448&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fully-diluted shares</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">774,943,928</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(727,394)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,021,844</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">780,238,378</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for issue</font></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,056,072&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,394&#160;</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,021,844)</font></td><td style="background-color:#DCE6F2;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,761,622&#160;</font></td><td style="background-color:#DCE6F2;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Authorized share capital</font></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">880,000,000</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-left:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">880,000,000</font><font style="color:#376092;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#DCE6F2;border-bottom:2pt solid #BFBFBF;border-right:2pt solid #BFBFBF;border-top:2pt solid #BFBFBF;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">20.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Financial risks</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in sensitivities for currency risk, interest rate risk, credit risk and liquidity risk per December 31, 2021 as reported in Pharming Group NV&#8217;s 2021 annual report and 20-F.</font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:36pt;padding-right:13.5pt;text-align:justify;text-indent:-18pt"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">21.</font><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.36pt">Events since the end of the reporting period<br></font></div><div style="margin-bottom:3pt;padding-right:13.5pt;text-align:justify"><font style="color:#494949;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant events since the end of the reporting period</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#59595b;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_greyxoriginalx.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo_greyxoriginalx.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M?#4Y<Q6=UHVUGU^Z<)[G)KRCU!Y3SRF.ES(FT;ZSLM'IB>'?&,=Z9!Z>]U
M
M
M
M
M
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M-JZ3F<Q%YV5S-T3W6X1/XMT\<-\Z>CC.Y3
M
M
M
M
M
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MN8T3$QC#]"*
M
M
M
M
M                                           $6N7W+[9WA5L[>-X-
MX+Q["D@[J?%,4IW,6Z7^Z*Q7Q45%$]4[GNTU>]?5C;JYRHB'L_E+REK.=:R-
M/IXV\9X5CMG]L9G9#U3SEYRT7(]%.HU$[-T1&^T]D?MA$;9=>CS#Y?[N<U]Y
M[[O%NS=7/DJ7208=B$4CG6W'K0DKGPT-&Q4:G:Q%U?(J(Z1^KW=5/T!\H>4=
M)R71QI\B/3/&T\9G_#A&R'YS><_.6LYYKK:G43_#7A6O"(]\\9VRBN>T/4P
M          :2_$!YDW;'LL'%[EAD<M3LYK'2;7;JU3GS2XHJJC(Z"O=ZSG6W
MKI%)U6F_!7^!T]CQSZN='_ZWQ:W0U_6WVI'S]\?B[8^;^+?R:Z-=:OZ#PZ'7
MV_1W4O/R=T_A[)^7^'[NRBDJZ2X4E+7T%5'6T-;&R:BK87MDBFBD:CV/8]BJ
MCFN145%1=%0X>WI-9PG9,.:E+Q:(F)QB7D&6@
M
M
M
M
M
M      "-_*OE7L_PYV?OV\V\U^2V6*V)[&R62'L?<[W<WL<Z&@H(7.;[2:3M
M7Y4:QJ*]ZM8USD]C\K>5M9SC61I]/&-IWSPK'&9GA$?;NC:]9\V^;=%R716U
M.IMA6-T<;3PB(XS/V;YPB'7N\X^;6['.S>JX[L;E3):[11-?1[=;>T\KY+?C
MUI]HKVP1=R-]I,]='5$ZM1TC_D:QK&,Y^^2?)>DY'HHR,G;,[;6XVGM]'9'"
M._&9_.GSYYYU?/\ 73J,[96-E:QNK'9'?VSQGNPB(;'N#TL
M!H;\1OF1N7&M^.<:^3-RGOFP-3/'383N#*^2:LPE)55J12M[7NGMO<J>JB]T
M":JSN9HQ./W5CH_7F7BUFCC#4;[5X7_PM_NXX3M<C>CW6FW+/#HM;,SI\<*V
MXY?=WU^VO#&-C:E;+G;;W;;?>;-<(+O9[O!%56JZTLL=1355-41I+%+%+$KF
MO8]KD<US55%1=4Z'#/-RK4M-;1A,;)B=\2YOY6;6]8M68FLQC$QNF.V'G&'4
M
M
M
M
M
M                            X,Y(<B]K.*FS^6;V[PWY+)A^*1:I"SV;
MJVY5LB*D%#11/<SVM3.Y.UC-43TN<K6-<Y/.>7?+VJYKJZZ;3QC>WLB.,SV1
M'[;7@?,WF72<IT5M5J+84K[9GA$1QF>'V[,77P\^.?&[O/C=V?/,\G=8<&L+
MIX-K=K8)W24%AH)')JJKHU)JN9&M6HJ%:BO5$1$;&UC&\_/(GD32<ATGY65M
MO/WK<;3[HCA'#TXR_.KJ#U!UGF'6?FYOPY=?N4X5CWS/&>/=$1$05/>'H0
M              OL\2WF"R/B?=K#L#R#N]1DG&.Y3>PL=Z>U]37X/-42=WM8
M>U'22V]7.59J=-5CU62)->Z.3X3U6Z1Y?-:3JM+$5U,;XW1?T]ENR>.Z>$QR
M!Z0=9<WE%ZZ35S-M+.Z=\Y??';7MCAOCC$[>K'?++D]EM.28W=J:_P"/W^F@
MK+'?*.>.II*RDJ8TFBFAEA5S'QO8Y'-<U51475#A5GY%\J\TO$Q:)PF)V3$Q
MPESJR,^F;2+TF+5M&,3&V)B=TQ/8]J=)U0
M
M
M
M
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MGS;9>;6:WK.$Q.R8ESQT6MR=3DUS<JT6I:,8F-L3'<^E.V=T
M
M
M
M
M
M           <9[P[P[;[![;Y5NWNWE5-AF X93.J;[?:ERZ-35&LBB8U%?+-
M*]49%$Q%>]ZHUJ*JHAY+E'*-3K]37(R*S;,M.$1'[;(CC.Z(>+YSSG3<OTUM
M1J+13+I&,S/[;9G=$1MF=D.O[\EGD<W!Y_;LON"NK,4V*PV:1FU&V,DK52%F
MGLG7&N2'U)*VH3JO5R1-7V;%5.YS^>W3?IWI^0Z3#9;/M]^WNC\,?;OGLC\\
M>I_4O4^8=9CMKIZ?<I_-/XI^R-D<9FM0^D/F(                    "Y3
MQ6>6',>"N2-VWW'^>YQQAR>I62[8W$[VU=C59,[5]PM;97-16N7K44VJ-?\
MAM5'Z]_Q[JCTJR>>9?YV3A34UC9/"T=EO=/#=NW?:NDW5W.Y!F_DYV-]+:=L
M<:S]5??''?&W?NUV]W"PG=?"<9W'VXR:DS+!LRI(Z[&LEH9$EIJNFE3HYJ]%
M145%:]CD1S7(K7(CD5$X.<PY?GZ3/MDYU9K>LX3$[XG]O:Y\\NYCD:O(KG9-
MHOEWC&)C=,?M['V1V;O0
M
M
M
M
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MQ,?MO[8WQ.R7WQV#R
M
M
M
M
M                                    ?,YIFF)[=8GD.=YWD-)B>'8G
M235V29)73,IZ2CI*=BODEED>J(B(B?Y?0G4[G1Z/-U&;7*RJS:]IPB(WS+M=
M;K<G39-LW-M%:5C&9G9$1#!'Y3O*=FW/'-I,+PN2KPWC)AM6Y^'8<]RQ5-\J
M8E5C;K=6L546145?8PZJV%J_*]7.7G;TOZ7Y'(LC\S,PMJ;1MGA6/IKW=L\?
M1A#\_.K'5C/\P9_Y65C32TGX:\;3]5N_LCAZ<95#'UI\<
M          !:%XU/)QNAP%W!@HIYJO-N/.4U37;C;5^VU]DZ3MC=<K6DSD9#
M6QM:FJ:HR9J=C]%1DD?S+J1TTTO/M/C&%-16/AO_ "V[:_;&^.,3]4Z8=4M5
MY>U.$XWTUI^*G\U>RT>R=T\)C?7LYO+MGO\ [<8QNSM#EU+FN!Y=3MGL][I7
MZIU3UX9HW:/AGB=ZLL4B(]CD5KD14.!_..3ZG0:FV1GUFF96=L3^^.V)X3&R
M7Z$<EYUI>8Z:NHT]HOEVC9,?NGLF.,3MAR<>,>4
M
M
M
M
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M'N<T'AGFP
M
M
M
M
M                      /57R^67&++=LDR2[4U@Q^P4T]9?+Y63QTU)1TE
M-&LTLTTLRM8R-C&JYSG*B(B:J=7(R+YMXI2)FTSA$1MF9GA#I9^?3*I-[S%:
MUC&9G9$1&^9GL8:O+YY8KES(R2HV0V.NE79N,6)52_/*Q%DIILVN%/(BLK*F
M-4:]M%$YNM+ _JJZ2R(C^QL7-SI)TJKR?+_J=3$3J;1Z?!'9'XIXSZHV8S/
M[K)U=MSK-_I=+,QI:SZ/S)CC/X8^6/7.W"(HN/M[X*
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M=FQ>P?#GWP
M
M
M
M
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M6FUIWS,XS/KE]TTNDRLC+BF76*UC=$1$1'HB'O3H.X
M
M
M
M
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M7MMF9G&9],RYCZ31Y6GRHR\JL5I6,(B(PB([HA]"=N[D
M
M
M
M
M
M_CG-8USG.1K6HJN<JZ(B)UU74#'5YG?+U)NE5Y#Q*XKY=_\ XMIO:T6\FZ%O
MD5/ZR3M<L<MKH)XW=;<W32>5O_.%U:U5A15FY>]'.DG]+%==K:_J[Z5GY?Q3
M'U=D?+O^]NX8=;.L?]7-N7Z"WZ6Z]X^;\-9^GMGYMWW?O9FCDFXO
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M)XUF)C[./=O?3'8/)@
M
M
M
M
M                   &1WS/^7^FRF')^'_%/*5DQ_OEH=[MW[=4:,N*-[HI
MK-;)H5]:GU]6JG:NDFBQL58^]7\L>CG2.<J:Z_75^+?2D\.RUH[?ICAOG;AA
MP]ZV]98S8MR[06^'=F7CCVTK/9]4\=T;,<<LQR?<40
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MWG\,SNG\,^J9W180?%7((
M
M
M
M
M                    #*MYG?,$VV-S7AMQ9OR.N;DJK1OONS2NU2E1>ZFJ
MK+;)$_SOX4=7.GX'6-GK]SF<H^CG2/Q>#F&MC9LG+I/'C%K=W&L<=\[-_$SK
M9UE\'CY;H;;=M<R\<.$TKW\+3PW1MQPR6G*UQ"
M   !I?\ #-X@ZK=.OQ?EMRDQ9&;44:LK=HMJ[C JNR>9/6AN==#)II;F+HZ&
M)R?ZPNCG)['1)N-W6+JW&EK;0:*WZL[+WCY>VL3]7;/R_P 6[D_T4Z-SJ[5Y
MAKJ_HQMI2?G[+3'T]D?-O^[][8VUK6-:UK4:UJ(C6HFB(B=-$T.(#FB_H  !
M^4\\--#-4U,S:>GIVN?/.]R,8QC$[G.<YVB(B(FJJIJE)M.$;9EF]ZUK,S.$
M0HDYL<Y:S<2HNNT^SUU?1[>Q=]/E&50JK)+ZOX+XH7)U;2?(JIUE_P"1T=R_
MZ4=(ZZ&M=9K:XY^^M9^3OG\7^WT[N"G6OKC?F-K:'E]L-/&RUXWYG;$?@_W?
MP[ZNSD$XO@         !_6N<QS7L<K'L5%:Y%T5%3JBHJ$F,5B<%T?"'G9+=
M9;5L[O?>N^Y2>SIL'S^I<B?.%T2..CKI%T_A%Z)',[\)>CU[M%=Q7ZL]((RX
MMK=!7X=]Z1P[;5CL[8X;XV;(YG]$NNDYLUY?S*_Q;J9D\>RMY[>RT[]T[=LW
M '&5R]
M
M
M
M
M   #,?YG?+[/M@[(N(W%?)VMW#GBDI-Y=VK?.BNQYK^Z.6TVZ6)?5KU3I43-
M7_5T7L:OMNY8>2W1SI)&I\.OUM?T]]*3\WXK?A[(^;?/P[^+?6SK).D\7+]!
M;]3=>\?+^&OXNV?EW1\7W<>KG.<Y7.57.<NKG+U554Y=.&;^
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MS\O?/XNR/E].[@WURZVSKIMR[06_1C9>\?/VUK^#MGYOX?O54G(EQ6
M        7'<)>>$B26;9S>^[-6%6QTN%;A5+U1R.1>R.EN$CUT5%31L<R^CH
MC]=>Y.+_ %8Z/QA;6Z"NW?>D?;-8_?7V=CF+T3Z[3C3E_,K;-D4S)^RMY^R+
M>JW:N6.+CF0
M
M
M
M
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MC*BO+^97^&-E,R>'96T]GTVX;IV83%T**CD1475%ZHJ>A4.*[F=$OZ
M
M
M
M
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ME'W=?K:]]*3_ +K1_MCU]CAUUVZUQA;EO+[]V9>/MI6?]TQZ(XJ;#E$X;@
M                MMX-\Y%QM;1LQO/=]<<7LIL'SBI?UMZ]&1T=9(]?^;_)
M'(O\7^"[U-%9QLZM])/S_%KM#7X]]Z1\W;:L?5VQQWQMW\M.A_7#^F\/+N8V
M_3W4O/R]E;3]/9/R[I^'[MVR*CD1475%ZHJ>A4.)[FS$OZ
M
M
M
M
M                                    41^7GRV6WAY9:_838RMAO')S
M):-KKA=E8R>DPJ@JX^Z.JF:]%9)72,7NIX%14:FDLB=O8R7[ETEZ46YO>-5J
M8PTU9W<;S'".RL<9]4<9CX%UCZP5Y+2=)I9QU5HVSPI$\9[;3PCUSLPB<.%W
MNUTO]UN=]OEQGO%[O51-5WB[U4KYZFJJJF1TTLTLDJJY[WO<KG.<JJJKJIS:
MRLJN72*UC"L1A$1NB(X."&=G7S+S>TS-IG&9G?,SOF7KSJ.F
M            %S_B=\4^5\WLQHMTMSZ*IQGBWA]:W\=714D@J<LJZ:1%?;+>
M].UR1:IVU52U?435C%]IJK/CG57JEE<DR9R,F8MJK1LCA2)^:>_LCCOG9O\
MMO2+I+G<]SHS\^)KI*3MGC>8^6O=]4\-T;=V[_&,8QS"L<L>(8A8Z7&<6QFE
M@H<>QZA@CIJ.BHZ:-(HH88HD:UC&-:B(B)HB'!G4ZG,SLR<S,F;6M.,S.V9F
M>,N?>ETN5D949>7$5I6,(B-D1$;HB'O3H.X   "HWG5S>BL<-ZV2V>NOM+[,
MCZ7/,UII%TH&KZDE%221KUG7JV61%_@^K4]?56<E>D/2:<V:Z_6U^#?2D\>R
MUH[.R..^=F_B1USZW1D1?EO+[?J3LS+Q\O;6L_5PM/R[H^+'PTFG*YPI
M                 6O<)N=E1B$EFV@WHNOML.5&4N(9O.Y5DM2Z]L=/5O<O
MK4WH:R1>L7H7^#ZLXY=5^D%=3%M;H:_J[[4CYNV:_B[8^;AMW\K>BG72VCFO
M+^8VQR=U+S\G96T_3V3\O'X?NWB,>R5C)(WI)'(B.CD:J*US535%14]**<2I
MB8G"7-^MHF,8?Z(H
M
M
M
M
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MCY/PU_'VS\O\7W:+7.<]SGO<KWO55<Y5U557JJJJG+N(P<&IG%_"H
M               6I\(><JX%^+=H=Y+LY^#^K#B&93N5SK.OH;35+EU5:7Y&
M/_S7H7^#_ X[]6>D?]9CK=%7];?:L?-WQ^+MCYO3OY3]$>N/]!X=!S"WZ&ZE
MY^3\-OP=D_+_  _=O,@GAJ88:FFF;44]0UKX)V.1['L>G<US7-U145%U14.(
MUZ36<)V3#G)2];5B8G&)?J9:
M
M
M
M
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M.=JJJJKJJJ<Q:4BL81LB' V][6M,S.,R_(TP
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ME!@DK:KQ:;[0P7.QW2FO-MJ41U-<:2>*H@D:J(J*V2%SFJFBZ]%"/8@
M        XJWSW5M^QNSNY>\5UM4U]MNVEEK[S76:G>R.>IBH('3NCC=)ZJ.<
MC=$5>@%&?_>']F?\.V3_ ,ZVK_S28M>$_P"\/[,_X=LG_G6U?^:,3PG_ 'A_
M9G_#MD_\ZVK_ ,T8GA/^\/[,_P"';)_YUM7_ )HQ/"MWX;<JL?YD[*4.]>,X
MI689:ZZXW"W,LE=-!45#7V^1L;GJ^GT;H[NZ(5E*H
M
M
M
M                      51^3_R?X!P%P!;'8UI<TY'YI2O=M[MZYZOAH(7
MJZ)+K=4B<CF4K'(OLX]4?.]%:U4:CWL^I],NF6HY]J/%;&NFK/Q6[?PU[^V=
MT1MGA$_).JG533^7M/X:X7U-X^&O9^*W=V1OM.R.,Q@2W#W#S7=C.,HW(W&R
M2JR_.,SK):[)<CK972U%54RKU557T-:B(UC4T:UJ(UJ(U$0YX\OY?DZ3(KDY
M-8K2L81$<(?GOS+F.?K,^V=G6FV9><9F=\S^WL?&G>.R
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M/X=UZ9Q$<Y@                   ,/_FM^T+W6_)F+?5VD)+=54(4
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M*$
M
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M6KI9VH]DD;V*J*BHO^3T+U*R^B
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M,-]L[@J&[5;<.>OLU6/^#=<KBL2HZ.BA<NFB*CIGI[-BIH]\?TOIMTYU'/\
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M9[BY%^;I L.OD(V   &UGP9_ 5C_ +SY)])C*Q*X4(
M
M                                                 1[Y6;]VGC#Q
MYW5WSNT$=:F!6Q\UGM<KG-CK;K4R,HJ"F<K/61LU5-&QRIU1%5?D"Q#KV-Q-
MP<PW7SG*MR,_ODV1YEFE;/<,AO,[E<^:HG?W+HGH:QJ:-8QNC6-1&M1$1$(V
M^,   -$_@=Y@W?'=Q+KP_P QNKZK$<ZBK;MM/'*Y7_B^]T<+JRMI(NY?5BJJ
M>.2;M]"21JJ)K(Y5,S#5N5D
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MM=/IZ^'+KNCWSVS/&7YW<^Y]JN9ZJVIU-IMF6G;/NCLB.$.)3RKQ
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MJY>76*TK&$1&Z(?G?K]?G:K.MG9UIM>TXS,[9F9>I.Y=H
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MW*SW%R+\W2!8=?(1L   -K/@S^ K'_>?)/I,96)7"A
M
M                                                 "C7S^9-4VCA
MO@]AI)G1?UMSZTPW%B([LDI*2RW6M5KE1437VT<3D1=?1]XDM58ZPT   $H^
M$.45&&<Q>+N14\KH4I,]Q6*M<S57K25=YIZ.I:B(K=5=#*]NFNG7KT!+L.RN
MF
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MKGFJJJ9]34U+W25%1(Y7R22/57.<YSE55557554Z[RL1@_(*         /\
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M70+B@->+->,>N=;9;_:JFQWFW/6.X6FL@EIJJ"1$U5LD4S6O:[KZ%0*]8
M  $D^*O*G=7B#NQ:-UMK+JL51 K8,HQB9S_Q=?+8KT=+1U<;?2UVFK'IZS':
M.:J*@);RN,7)3;;EAL]C.\FV%>LUGO;?97>S3*U*VT7.)K5J*&J:WT2Q*Y.J
M='-5KVJK7(JUTY2!     "'GD&^![E9[BY%^;I L.OD(V   &UGP9_ 5C_O/
MDGTF,K$KA0@
M
M                 !4!YP]L;KN)P3O=YM,+JF3:7)+)D]=3,1SGNI&,JK#,
MY$;\D;;HLCON-:J_(%AB@(V   $\/&3MC==U>=G&RS6R%SX\7R2BR>ZU*([L
M@I,6?^/G.>J>A'.I6QIKZ7.1/E"2WW%8
M                                       !E7\AU=5\/_+ULSRKNU(]
M,(S=<>NMUN;&ND1:6AHF8=>(F-];66&BC9)VM33UV_*JD:C<MF\P%?177QH[
M_P!TME7'7VVY0X9/;Z^%[9(9X)LYL<D<C'L54<US5145.BH5(0A\.O&;8+?S
M@5F-MW;VEL.:37W+,@MU3?ZNV4;[O#3?BZW=GS>O]G\XA=&YZNC=&]%:[JG4
M$[U>GCQW)RC@;Y)\@XXY3>YXL%RS(Z_ <KIIG21TU35)6OI['<TB_!1SYO9(
MV1432*=_712-2M$\^6^MGQ/CAANPM'5QSYAN_>Z:NK+6B]TD5CL3EJ7RJC>K
M5?5K R/7\)$?I^"NB4JK\_4Y[B?]E*C_ -@?]9OP4_\ :A_^"_\ Z;[_ */O
MA<6NHK     (6\YN<VS_  0V?J]R]RZM+ID5T2:GVUVUIYF,N>17-C$=[*+N
M1WLX(^YKJBH<U6QM5.CGN8Q_N?DCR1J^>ZN,G)C"L;;6G=6/?,\(X^C&8](\
M^>?-%R#13GY\XVG96L;[3[HCC/#OF8B>O:Y1<G-UN7>\N4[V[OWE;EDF1/[+
M?:XG2I;[/;HW.6GH*&*5[_94\*.71NJJYRN>Y5>YSEY^^6/+6EY3HZZ;3QA6
MO'C,\9GMF?\ *-D/SH\U>:=7SG6VU6HG&UMT<*QPK$<(C_.=LRCV>P/70
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M,(B/V]L[YG;+\WN;\WU.OU-M1J+3?,O.,S/'_+A$1LB-D;'SAWSQH
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MZKY44\PZB(^J)]M8E^E'13.MF>5M+,_3,>RTQ'V0E,?/7U(
M    ,/\ YK?M"]UOR9BWU=I"2W55"%  '.O%WXF..WOUB/U@I 2[&DKI@
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MDGTF,K$KA0@
M
M                 !Z#*L7L.;XQD6&Y5;([UC.64-7;<AM$R:Q55%70.IIX
MGI_P7L>J+^Z!@^Y^\"-R.$NZ%QM];;JJ^[-9#52NVOW*]GW4]33OUE91U3XT
M[8JV%NK7L=V]_:KV)VKTC<2@"% /8VBSW;(+I;['8;747N]W>:.GM-GHX):F
MJJJB9R,CBBBA:Y[WN<J(UK4557T ;.?$;X[KGQ$P>[[J[M4D<6^^Z-)#!4V9
MJLD_JW8^YE2V@5[=4=4S2-;)4JU5:BM8QOX+G.K$RN4"
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MW2Z7&]W&NN]WK9+C=+G*^>OKYGJ^6:61W<YSG.ZJJJIW+RM:Q$80\$-
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MUGP9_ 5C_O/DGTF,K$KA0@
M
M                              ]!E&*XQF]AN>*YECM#EF,WJ-8;OCUR
MI(*ZBJHE]+)8*EKV/;]Y44"K/<GPF\"]P:ZJN5MPJ];8558Y[ZAN-WR>&#O>
MU4]2GNS+A#&B*NJ-C8UJ:>C3H%Q<76;P$<)[75)45V6;A9'"BMUH:R^61D2Z
M+JJ:V^RTK^OH7UOW-!@>)89Q_P"#O%;C Z.LV9V<MF.9"R-T;LRJ$FNE[<U_
MX:)7W-\\[&O_ 'S(W-;\FFB(#%+ (
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MEVN%]OMPENMXNLKIKA<)G=TDLCO2JK_XD1.B)T3H=R\M6L1&$/5AH
M          -)?B \R;MCV6#B]RPR.6IV<UCI-KMU:ISYI<4551D=!7N]9SK;
MUTBDZK3?@K_ Z>QXY]7.C_\ 6^+6Z&OZV^U(^?OC\7;'S?Q;^371KK5_0>'0
MZ^WZ.ZEY^3NG\/9/R_P_=V44E727"DI:^@JHZVAK8V345;"]LD4T4C4>Q['L
M54<UR*BHJ+HJ'#V])K.$[)AS4I>+1$Q.,2\@RT               8?_ #6_
M:%[K?DS%OJ[2$ENJJ$*  .=>+OQ,<=O?K$?K!2 EV-)73
M*6/,AP0HN1>SM;OQ@%G[M[MEZ"6>>.!C?:W[&J=75-31O3HKY:9%?/3Z:JOK
MQHBK(W0L2QD$;   "QKQ3\@I>/7-?:BZ554M/BFY4_\ 4[-&:Z-6DOTT<%-(
MY55$1L-:VGE<JZ^JUWW0DPWB%8   "'GD&^![E9[BY%^;I L.OD(V   &UGP
M9_ 5C_O/DGTF,K$KA0@
M
M
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M/(-\#W*SW%R+\W2!8=?(1L   -K/@S^ K'_>?)/I,96)7"A
M
M
M
M                  #AGD!O[M?QBVER_>O>'($QW!L-@22NG:WVM34SR.2*
M"EI845%EJ)Y'(R-B*G5=55&HJIYCD'(=5S/5UTVGKXKV]D=LS/"(XO">8O,.
MEY5H[:G46\.72/7/9$1QF9V0Z^3R%<_MSN?N\DF<Y2U^,[=XPDU)M3MC'.Z2
MEM% ^3N=++IHV6MJ-&K43=J:Z-:FC&-1.?G3_P A:;D.C_*I\69;;>W&9]U8
MX1Z]\R_.OJ-U#U7F'6_FYGPY==E*<*Q[[3QGU;HA 4]\?/@
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M&R-\\;3QF>^?LW1L?FEYS\XZWGFOMJM3.,SNCA6O"L=T?;.V=LN*3V-ZH
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M54Y4Z:]EONT5.B:>GK5]?O>E6*>%;CQ]\E'#;DI4T5GP'>&CM.7U[FQTV"Y
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MX4]7'MGT0_//K)U(MSWF$Y>5/_C94S%>RT[IOZ^'9'?,JACZT^.
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MR,B.^UIWVGMGW1PA^:?GOSUK?,&OG4ZB>ZM8W5KV1[YWS/LCA<]J>E@
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M<[#'DR[/;7UBO9'M[C4\U,Z>G<NB,K[@G;452JG1[=61.]/LD(U$*Q0H
M   !9KP[\J_)OB746O'WWV3=S:&D6..;;*_54TJ4M,SIV6RM>DDM$J)^"U$?
M$GI6-5ZA)AKVXD<T=C^9V#.R_:6^N;=K6V),QP&N]G#>;+-*B]K:B%CG(Z-Z
MM7V<T:N8[141>Y'-2LS"680            #B;>;?7:+CUAE7G^\^?6_;_%J
M55:RNKI=):J9&J_V-+3Q(^:IF5$54BA8YZHBKIHB@9N.5GGUS&[U-TQ3B-A<
M6(VAJR11[K9'3Q5ETF1%[4EHK:JOIX$U35JU"S=S5]:-B]"8M>%0ANKO5NWO
MED4F6;O[C7C<6_O5WLJZZUT]6D#'N[ECIXY'>SACU]$<;6M3Y$#3C
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MSVZK&D;B%$5145%943U=7.^JJJI[I*FID<Y\DDCW*YSG.<JJKE5=55?2%?B
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M^.#67<G:?,*+.,*O[.ZW7RBD[V=R(G?%*QR(^*:-5TDBD:U[%Z.1%*RY%
M     X*Y1?#-R*]Q,N^K]6!URQ'4    !9#Q(\I7*;B?<+9;:3+)MT]K*56,
MK-K<BJ9JJF93M1&]M!5R>TGHG-;KV)&JQ(O5T3_0$F&Q#B+S'V;YG;<-S[:F
MZNCKK8L4&:X/6=C+K8ZV2/O2*HC:JHZ-^B^RF9JQZ(NB]S7-;69A*T(
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MJC_9GO3'#WW+:FZ5,;I*ES&JZ1]JJE2-M;&U&JY41K96HBJZ-&IW+69A9.$
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MR\B(MZ;?+'[[?\+X7U^\XVY9R;\G+G#-U$S6.V*_//LF*_\ $P>'.=P#
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MO6XVG_#LCAZ<9G\V.H/4'7>8M=.?GSA6-E*1NK'9';,\9WS/9$1$<#GN#T0
M               <0[S[R8SLQB<]_O<J5-UJDDCQO'FN1)ZZI:W5$3T]L;=4
M62331J?=<K6KNE,6JUFTX0HYS_/\GW,R>ORS+*]:ZYURZ,8FK8::%JJK(86*
MJ]D;->B?NJJJJJJ]S$8/+965%(PA\85U0                         :
MOV=OD+5[<<P,BV*KZU6XQR&L52RDH5<B,3(,:AEN]++ZW_[HE8Q43357-^XB
M'P3^X/R_&HY174Q'Q9-H_P"6VR?M\,N0_P#;?YCG3<YMI9GX,^L_\U<;1]GB
MCV-O)PJ<Z0            ,/_FM^T+W6_)F+?5VD)+=54(4  <Z\7?B8X[>_
M6(_6"D!+L:2NF                *[O+%]GIR7_ "9:_K%;PL,&1&P   UB
M?L\3*I-D.0<CV2)1ORJWM@D5'>R65MH:LB-5>G<B.9W:==%37Y!#-FAHK(
MAYY!O@>Y6>XN1?FZ0+#KY"-@  !M9\&?P%8_[SY)])C*Q+AWR:^7BU;!2W_8
M7C774^0[UP^TI,RSW2.IMV*2:(UT,+7(YE17MU5'-76.%W1Z.>CF-BQ#)+D^
M49'FN07C+,OOM7DV3Y!/)57R_P!=/+55=742KJZ26697.<Y?NJH:>B
M     '+6R&^6Z''3<>Q;K;0Y3-B69V!7)!6QHV2&HIY-$EIJF&1%9-!(B:/C
M>BIZ%31R(J!NLX*<V< YO[/P9YC<+<?S6P.BH]S< =*DDUIN+F*Y',<NBR4T
MZ-5T$FB:HBM71[7(E8F$V @          5-^0KRJ;8<-J6NV^PN*EW.Y"U$*
M+!B#9];=8?;,[HY[O) O<UVBH]M*U4D>U455C:YKU+$,=F^W(3>+DKG59N+O
M3G-9FV2U**RD=.Y&4E!3]W<E/1TT2-BIX47KV1M1%75RZN556-N&
M      2+XS\J=Z>)6X-+N)LUE4EFK56-M_QV;OFM%YI6.[OF]?2HYJ2L75='
M(J/9KJQS7=0-N7!KG=M5SAVY?DN(.3&L_P =;%'N+MC43LDK;7.]-&RQN1&^
MWI)51?93(U->K7(UR*TK$PG"$        .!N2?([;'BKM)D>\6ZUV6@Q^Q-;
M'06R'L?7W6X3:I!1443W-]I-*J=$U1&M1SWJUC7.0,)7,?E_N9S/W?N6Z&X$
MRVZV4Z.IL$P2&>66@L-L1R*V&'OT[I7Z(Z>;M19']=&M1K6QU(A$\ !>AX2N
M;,VRN\?_ /;9G=V5FUV^%9&W%99Y4;#:,M<Q(8%;W*B(RX(UM.]$U59$A5-$
M[E4DPV'%8? ;I[HX)LKM]E.Z.YF0PXM@^&TKJN_7J?N5L<:.1C6,8Q%=))(]
MS61QM17/<J-:BJJ(!AY\AOD-W YQ;@(QB5&);'XE42+MUMTLB:N718OQC<?9
M*K9*R1JJB(BJV%JJQBKJ]\D;B%<P4     #7)^SU_#/O5[].^K]O$,V7]%9
M %9'F/\ LW^1GZ(?7RRA886"-@  !V*UXWVVUV8XWV+>W=+(8L0P:U8[:JVM
MJYU[I7.J*")\5-#&WUIIY'.1D<;$57.]!738W^?ODVW=YJWZMQN@FJ-O-@+?
M.BX[MG!+VRU_LG=S*J[RQ+I43*J(YL2+[*+1$:BN1TCXW$*R0H
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ML(W:V_N*77#\^M\%QL=5T1Z1S-]:*5J*O9+$]'1RL]+7M5J]4*PY%
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ME3#$B>AD-52K*[7]]/\ +\B&;-#960      $%?)I\!/*+W8G^DPA88"R-@
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M(86)ZL<,3$1D4;?5:U$1.B$;<;              _K7*U4<U5:YJZM<G145
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M7NM^3,6^KM(26ZJH0H  YUXN_$QQV]^L1^L%("78TE=,
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M-F-WZNJ;59#>[4RDS5R:(OX\M4CK97N5J(G;[2:!TK4_X+D5.BHI6)2V"
M    ,B?[0#L['B?([;'>2@I4@HMW<=?17:5&_P ;=L:G; ^1SONK25=*Q$^X
MS_P26ZJ#0H    /TBBEGEC@@C=--,Y&0PL17.>YRZ(B(G555?0@&A'@MX.\M
MW)H[-N?RYJ:W;C#ZQ(ZBT[0TO^KY'71*J2-6XR2-=\QC>G18D19]%5%]BY$U
M8,S9IEV:X];(\>L?3&=E=L+1MU:G-8RK6WTK6U57V?@NJJN7OJ*AR?\ "FD<
M[[Y67,@        "LCS'_9O\C/T0^OEE"PPL$;    !95X[O''N!SCS&:Z5<
M\^%;%8E4QQYSN#[)%EJ9D[)76ZVI(G;)5.8Y%<]45D+51ST558QY)EM/V*X_
M;1<;,"M^VVS.%TN&XS0HUU0V%O?55U0C48ZIK*B362HF<B=7O<JZ:(FC41$K
M#F4      'H\FQG'<SQ^\8IEMCI<EQG(:>2DOE@KH(ZFDJZ:9O:^.6*9'-<U
MR+U14 QL>57QE5'$B_.WDV@IIKEQXR^L]E);E62:?$KC4.[F4DTCM7/I)5U2
MFF<NJ*GLY%5W8Z2-Q*F0*     !R[L7L;N5R-W/QG:+:?'W9#F.42JVGBU]G
M34M.SUIJJJET5(H(6^L]Z_N(BN5$4-M' [QN;-\)L:I;E34L&>;X7*#MRK=F
MJIVI-'[1NCZ6V,D[EI:;KHNB]\OID<J=K65B96,A      /XYK7-5KD1S7)H
MYJ]45% RR>8/Q?V' +5>.6/'3'([-BT$B2;R;;44793V]:B54_&U#$WI'!WN
M1M1"Q$;'JCVHC._MC42S>AH   +TO COA)@O*;*MF:ZK6.R[YV*7YA2Z]'WS
M'&R7.G7KZ/\ 5'5B+]U=/N"&;-AA60       #CS=G:[#=[-M<TVHW!M3+UA
MV>4$UOO="]K55&2IJR6-7(O;+"]&R1/3JU[6N3JB ==%NKM_=-I]S]Q=KKV]
M)+QMS?;M8KG,B=K9)[37RT+WM1=?5<L6J?>4CJ/@0  "]/\ 9]OC+W,_W8WG
MZU8X(2S865@      !!7R:? 3RB]V)_I,(6& LC8    /(I:6IKJFFHJ*FDK
M*RLD9%24D3'22RRR.1C6,:Q%5SG*J(B(FJJ!J1\<WA:M%BI;%O7S(L;+SD,[
M8JO%-B)T1]%0-<B2,EO:)TFF]"_-/P&>B7O558PS,M'E'1TENI*6WV^ECH:"
MAC9#144+&Q0PPQ-1C&,8Q$:UK6HB(B)HB%9>2      #/;Y?/&)8MPL7RGE9
ML'CK+7N;C<4MPW7PNAA1D.14$35DJ+A#%$G2OA:BOE1$_AV(J]943VD:B63,
M-   !:OX9]ZG[0\Z-OK35UJTN.[QTM;B5Z8JJK'35S$J[?ZNNBN6MIH8T7TH
MCW:>E44DMPY6       &;/SU<P)+/9<9X=X3='15V1LIK_O%-!)II;V2N=;K
M=)VZ_P ;+'\YD:NBHC(E]#R2U6&6T-   !S?QYX\[I<H-TK!M'M'8'7O)KV[
MOJ:E_='0VRAC<U)JVMF1KDBIXD<G<[15551K4<]S6J&W7@_X\MDN$N*0)C-O
MCR_=JYTZ1YEN]6T[$N%4K]'/@I&JK_FE)W(FD3%U=HBR.>Y$5*Q,I]!
M /29)C6.YC8;KBV6V&CRC&K["^GO6/W"FAK**KIY$T='-!4->Q[5^5'(J 95
MO)7X;ZO:NCON_'$RU55ZVYHV2U>=;1(]]776&%B.DDJ[<Z5RRU%&U$]>)5=+
M%U<BOCU]G&HEGE#0    /L-OL/K]P\^PC +4JI<\YO%LL]N5&]RI/<ZV.BCZ
M=-?6D3H!V3%@L=LQFQ67&[+3)1V?'Z2FH;31M_!BIJ2%L$3$^\UC$0KIO;
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M@VC=69KDTR(J^P98X=*%_P!S_P!8STK>OW3Y7UGYU&B\OYNWXLS"D?\ %O\
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M@Y3\?=QV2^QI\7RVR2W9W=V=UNFKHZ6M9W?)WT\LC=5Z=>NJ= DNQ.*P
M     .OD\@OQP<K/?O(OSC(1N$/ H  O3_9]OC+W,_W8WGZU8X(2S865@
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MR6[&;:KF8QCO?JRGB7HLC^WHZ:335[ODZ-3HB'=5KA#RF1D12.]P::=P
M                           &U3]G>XF5.UG'O,.3666Q:7*>051'386V
M5NDD.*6:62-DK4<B.;\\JW2.5%U1S(HG)T4X9_W!>:XU7,*Z/+GX<F,;?QS_
M (1AZYF'-_\ MP\H3I.77UV9&%\^<*_P5_ZIQ]41+1.<>W)$
M##_YK?M"]UOR9BWU=I"2W55"%  '.O%WXF..WOUB/U@I 2[&DKI@
M     *T.??DQVBX58]6V"CJ*;<'?NO@1V-[80SZMI/:Z=M5=9(=5IX41>YK.
MDDO1&HC55[2Q#$[O%O!N%OWN3E6[.Z>0R9-F^8U'SB[W.1$8U$:Q(HH88VZ-
MCABC:V..-J:-:B(A&W&0    UV^![BM-MMLME')/*[7\VRG>Y[:/"O:L5LT&
M+VZ9VLB=VBHE;4M5^FFBLBB<BZ.$,VE?B5D   (>>0;X'N5GN+D7YND"PZ^0
MC8   6L>)+A3%RUY#1W[-;4E;LMLPM+=L[AE8CJ>Z5KY%6WVMR.U[FSOB=),
MFBHL4;FKHKVA)EN$8QD3&1QL2..-$;'&U$1K6HFB(B)Z$0K#_0         !
M0%^T%;54V0<>-H]WZ>G[[MMMD[[753(U/5MF14+W2.<[TZ-J+? UJ?\ &4DM
M59'@T   '8'>.K+79MP9XM7MTJS/I\.M-LDE7JJNL</XD=JJHFJZTG5?_&OI
M*Q*: 0    %6?F9K[G!X_=V;3:(IZBMRBOQFA;2T\,TTLK&Y#25[VHD**J)V
MTR]RKT5-4^4+#$I_4G,_^R-S_P"@57^C(WB?U)S/_LC<_P#H%5_HP8G]2<S_
M .R-S_Z!5?Z,&)_4G,_^R-S_ .@57^C!BW)^(_ /]GG '8FAJ+<ZVW?(HKQ>
M;XR1GLY9)KC?*N2)SVZKHJ4Z1,Z]=&IJB+T*Q*R0(         /SEBBGBD@G
MC;-#,U630O1'->UR:*BHO145/2@'7*\F-LV[,\A][MJ88UBHL RF^6NTZ]%=
M0TMQECI7]?D?"C')^Z1U'!X  !>7X!<PELG,/-L5?.K:+-L&N;&TW<J(^LM]
MUMU9$[3T*K8DF1/W5Z_(J&;-B960      %<7EMQIF4^/3D;2+#[::V45HN=
M,Y.Q'1K;,BM]<]R+)T3^#C<BZ=5151.JA88/B-@  !;/X@^&%/RIY%LRO-K4
MVX;/;'K2W;+Z29BNI[G<I)'+;;<Y%31S'R1.EF:NJ+'&K%_#0),MNY6
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M*BT;<RR6+:N*5J*Q]]J:5'UU8B.^6FIIV1QKU173.5-'1H(9LU9E9
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M],:L"JG<B.]59YU;JCIGHG[C4Z)\JN[JM<(>3T^1X=L[T?33N@
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MS3931OED>KU<UN6W.=G;KU1K62M8B?)I]PK$K1 @
M   PA^76STMC\BG)*BI$1L4]7C]8]$8UB>UN&)6JX2=&]->^9=5]*^E>JD;A
M6Z%  %L_A+JZBF\@VVD,$JQQ5]GRB&L9HGKQML51.C5U3_AQM7I]P0EFW<K
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MY;!8%=HZ5R:M^<U/:JHZ5R+T3JC$71-55SG=U6L1#R.GT_AVSO1O-.[
M                          "2/%/BKN]S&WBQ_9G9RQ+<KW=%2:^WR5'M
MMMCM;'M;/7UTS47V<,7<GW7/<J,8CGN:U?7/-/FG2<GT=M1J)PK&Z.-IX1$=
ML_9OG8]F\I>4M9SK6UTVFKC:=\\*QQM,\(C[=T;9=AKPNX:[2<'=EK3L]M52
M/J7*]*W-\TJ6M2XY!>'Q-CEJZCM548FC$;%$U>V-B(B:KW.=^?WG+SCJ^=ZV
M=1G^BM8W5CLCWSQGV/T:\D>2M'R'0QI\B.^UIWVMVS[HX1[4M3U-[@
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MV   &UGP9_ 5C_O/DGTF,K$KA0@          05\FGP$\HO=B?Z3"%A@+(V
M  &VKP@7%];P P>F?&C&V>_9-3QN15U>UUT?5ZKK\NLZI_D*Q*W0(
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MZL\NMHMRHL;ZR5J=OSFH;KU5>OLVK^"WY.Y5.YI3!Y+3Z?P[9WHN&W=
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MS-P]*>]               &'_P UOVA>ZWY,Q;ZNTA);JJA"@
M          $N.)'"G?3F9FS<6VHQY8[%;Y&)E^XE<V2&R6:)VBJLTS6N[Y5:
MNK((T5[O3HC=7(29;7>&'"#9[A+MTW#]O*1;SE=X;')GVYE9#&VZ7JJ8U/3V
MJ[V-,Q=?8T[7*UB+JJN>KGNK,RF2$      AYY!O@>Y6>XN1?FZ0+#KY"-@
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MP       AYY!O@>Y6>XN1?FZ0+#KY"-@  !M9\&?P%8_[SY)])C*Q*X4(
M        "LCS'_9O\C/T0^OEE"PPL$;   #>;XG?L].-'Y,NGUBN!6)6(A
M         IZ\YGP%9![SXW])D"PQ3$;   #?IXR_@)XN^[$'TF8K$IU!
M       JA\UWV>FZWY4Q;ZQ4@6&'\C8   ;]/&7\!/%WW8@^DS%8E.H(
M    =?)Y!?C@Y6>_>1?G&0C<(>!0 !>G^S[?&7N9_NQO/UJQP0EFPLK
M  ""ODT^ GE%[L3_ $F$+# 61L   -P'A1^STVI_*F4_6*K*Q*UX(
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M]T<ETF:NB3S-731B:?P3%ZI^$[JJ(WNJ4P>1TV1AMG>B2;=X
M                   '-''WC]NGR?W9Q39?9O&WY+F^6S*RFAU6.EHZ:-.Z
M>KJYM%2&G@9ZTCU^3HB*Y4:OAN?\_P!+RS26U&HMX:5]LSPB(XS/!YOR[Y=U
M?-=973::OBS+>R(XS,\(CC/O=@KX\_'[MAP!V?;A>+/;D^X^4I!4[K[FR1)'
M47>NB8J-BA:NJPT<'<Y((M>FJN<JO<Y5X"]0//VJY]J_S+_#EUV4KV1W]LSQ
MGU;H?HETYZ=Z7R]HORLOXLVVV]^-I[NRL<(]<[93^/0GT,
M  8?_-;]H7NM^3,6^KM(26ZJH0H                   ')6UFS>ZV]V2PX
M?M%M[=]Q<DF5G=;+313U;H6/=V)).^-JLAB1?3)(YK4]*JB :&N(?@0K9)[3
MFG,;*64]*Q63+LMC]4KY9.J.]E<;K"J-8G14?'2=RJBZMG:HP9FS2-M[MS@>
MT^)6C ]M,1H,'PZQ,5EJQVVTT=+31(J]SG=L:)W/<O5[W:N<NJJJJNI67V@
M      $//(-\#W*SW%R+\W2!8=?(1L   -K/@S^ K'_>?)/I,96)7"A
M      @KY-/@)Y1>[$_TF$+# 61L   -K/@S^ K'_>?)/I,96)7"A
M    ^+SS<C;W:RP3Y5N7G%HV_P :IETFOMYN-);:1'::HU):R2-JN7Y&HNJ_
M(@%3&]7G.X9;:2U5MP!]\WRO,&K6RV:A^86I)$U16OK+RM.Y4Z?A0PR-7Y%4
M+$*P-SOV@_D%?7U5/M-LSB^WE!-JV&KNTUQR*OC37HYKXGVV!'+_ ,:%R?\
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M3                  P_P#FM^T+W6_)F+?5VD)+=54(4
M^\QG:W<[-5C3#=N;]EJRHU8DMEHN%?W(Y'*FGS6*377L73]Q?N Q2IP3QI<\
M=Q70I8.+^44#9OP)+Y2Q8TS1'=NJKD<E#HGRI]U.J= F*?&UG@#Y3Y4ZEJ=T
M-P,6VGMLJM^<TL4M5D%UA:O5R^PHV04SE3Y$2KZK][J,$\2U/8_P3<0=MI*2
MY[G5U[WXO=.J.DIKC4K:+*KV]6N;1VAS)EZ]5;+4R-7T*FFNMP3Q+=]O]M-O
M-J,=I<1VRP>U8!C%&B>PL5HH*:WTR.1$;W*RF8Q'/73UG.U<J]555"/MP
M      "'GD&^![E9[BY%^;I L.OD(V   &UGP9_ 5C_O/DGTF,K$KA0@
M      05\FGP$\HO=B?Z3"%A@+(V   &UGP9_ 5C_O/DGTF,K$KA0@
M !QONON_MCL;A=SW#W<S:@P'#;2B?.[W<)O9L<]R+VQ1,:CI)I7Z>I%&USW?
M(B@9J^6_GORJ\3U^(\/\5;BEH:KXI-V,AI8JFYS:*K4DH;<YTD$+>FK75'M%
M5%ZQL4F+454 [F[N;H;SY+49ANQGUVW#R:HU1UWNU=/6RL8NG\'%[9RI'&FB
M(C&(C43HB(&G'8               "U[PI?:%[4_DS*?J[5B$LW %8
M 0\\@WP/<K/<7(OS=(%AU\A&P   VL^#/X"L?]Y\D^DQE8E<*$
M !61YC_LW^1GZ(?7RRA886"-@  !O-\3OV>G&C\F73ZQ7 K$K$0@
M  4]><SX"L@]Y\;^DR!88IB-@  !OT\9?P$\7?=B#Z3,5B4Z@@
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MO3KZ%0^R\H\Y\IU\?H9]+S/#Q1C_ ,LX3]CXASGR/SCE\S_49%Z1''PS-?\
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MI6?E[Y_%V1\OIW<&>N76W^O\7+M!;]#=>\?/^&OX>V?F_A^]58<B'%@
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M ",_1#Z^64+#"P1L   -YOB=^STXT?DRZ?6*X%8E8B$          "GKSF?
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M^+LCAQV[N$?6KKM_6Q;0<MM^ENOF1\_X:_A[9^;='P_>J>.1SBB
M       /\O>R-CI)'(QC$57O541$1$U555?D J>Y7<H/ZZ2U6W&W=Q<W$:=S
MH\DOL3M$NLC5T]E$Y.OS=JIU7_.+_P 5$[NYRZ8.^TN1\T^I LZCOP
M                         ^QV]V]S;=?-L9VXVXQFKS'.<QJXZ'&L:H8U
MEJ:NIE7HUJ=$1$1%<][E1K6HKG*C454[/F',,G2Y-L[.M%:5C&9G=$.]Y=R[
M/U>?7)R:S?,O.$1&^9_;V-[OBM\8.(\"=NWY)E[*/+.2F>4[/Z]YG&Q)(;12
MO1LGXHMLCT[D@8YJ+-*B(LST15]5L;6\$NJ/4S-Y[J/!EXUTU)^&O;/U6[^R
M.$=\R_0/I-TLR?+^F\>9A;57CXK=D?37N[9XSW1&%MI\H?8
M       ,/_FM^T+W6_)F+?5VD)+=54(4  <Z\7?B8X[>_6(_6"D!+L:2NF
M                        !#SR#? ]RL]Q<B_-T@6'7R$;   #:SX,_@*Q
M_P!Y\D^DQE8E<*$          ""ODT^ GE%[L3_280L,!9&P   VL^#/X"L?
M]Y\D^DQE8E<*$      A3SPYHX7PDV2N&X=\;%>LXOJRT&U>#N?H^ZW;V7>C
MI$8YKFTM.BH^HD14T31J+WO8BEB&#[=O=G/M\MQ<JW4W.R";)LTS&J?57>YS
M.<J)KT9#$U55(X8F(C(HV^JQB(U.B$;<<    #EG:78C>;?B^.QS9O;&];D7
M:)6_/(K503U45*U^O:^IG:WV4#%T_"E>UOWP+==H/ =ROS6*BN&Z>7XWLO05
M*-6IMCZB7(+Q!KU5%@MG;2*J?>K!@F*Q' ?V>[CI:(8'[D[TY?F]=&B^U2UQ
MVFP4DCEZ=8IX+G*B?>2;77Y?D&">)*_&?"_X\\>]DZLV<K,LJ(51S*BYY-DB
M]4>KO6CH:VEB<G5$T<Q4T3T:ZJM3%R_;/&'P%M,<$=+Q?QR5M.[OC6I;75KE
M7N[O6=65$JN37Y'*J:=/0#%]=^KYX/?X4\%_L[;O]&#$_5\\'O\ "G@O]G;=
M_HP8GZOG@]_A3P7^SMN_T8,3]7SP>_PIX+_9VW?Z,&+'7Y4=OL'VKYY[[8'M
MOBE!A&%V+^K'XFQ>V4T=)14OSK#;36S>SBB1&M[Y9GO=HG5SE7Y2-0KX"@ "
MU[PI?:%[4_DS*?J[5B$LW %8       0\\@WP/<K/<7(OS=(%AU\A&P   VL
M^#/X"L?]Y\D^DQE8E<*$           !61YC_LW^1GZ(?7RRA886"-@  !O-
M\3OV>G&C\F73ZQ7 K$K$0@          4]><SX"L@]Y\;^DR!88IB-@  !OT
M\9?P$\7?=B#Z3,5B4Z@@          50^:[[/3=;\J8M]8J0+##^1L   -^G
MC+^ GB[[L0?29BL2G4$        .OD\@OQP<K/?O(OSC(1N$/ H  O3_ &?;
MXR]S/]V-Y^M6."$LV%E8       05\FGP$\HO=B?Z3"%A@+(V   &X#PH_9Z
M;4_E3*?K%5E8E:\$          ""ODT^ GE%[L3_ $F$+# 61L   -P'A1^S
MTVI_*F4_6*K*Q*UX(   $$_)O RHX$<H8Y(4G:W&97HQ6HY$=%502-=HNO5J
MM147Y--0L,!I&P   VY>$>O@K/'YMY3Q(Y)+5>LHIZK5$1%>Z\S52=O7JG;,
MW_+J5B5M@0            #"SYC_ +2#D9^B'U#LI&X5CA0 !9QX</M(..?Z
M7_4.]!);IBL              /QCJ:>66>"*=DD]*K4JH6N:KXU>WO:CD1=4
MU1=4U^0W;+M$1,QLEBN969F(G;&_N?L8;          #BW=?>C;;93'WY'N-
MD\%BI7([YA0JOM*VM>W3U*:G9J^1W5-=$T;Z7*B=3V'RYY5U_-L[\K34FT\9
MX1Z9W1[^#U?S7YSY;R73_G:S,BD<(WVMW5C?/NXX0H6Y2<Y,ZW]=68KCC9L'
MVL5VBV%DB)6W-K7:M=7R1*J*WIJD+5[$7TJ]414YB=/>DFCY-AG9N&9J/JX5
M_AC^:=O9AMAP-ZH]<-=S^9R,G')TOTX_%;^.8_VQL[<<(E!8^O/A@
M         _BJB(JJNB)Z5 JPY7<I69*EPVPVWK^['FJL6591"]?]?5JZ.IZ=
MS5_B->CWI_&>A/4U5_<Y>7AOWN[TV1XOBG<KX.H\D
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M"2W55"%  '.O%WXF..WOUB/U@I 2[&DKI@
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MQ&,S.R(B.,NKD9%\V\4I$VM:<(B-LS,[HB.UND\1_B<QWAKBMJWLWEME/?\
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ME8       05\FGP$\HO=B?Z3"%A@+(V   &X#PH_9Z;4_E3*?K%5E8E:\$
M        ""ODT^ GE%[L3_280L,!9&P   W >%'[/3:G\J93]8JLK$K7@@
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MS&,,_4WF)X1/ACV5PC[' JJJJJJNJKU55]*J>XO0W\"
M  KAY9<HW4"U^UNVMS1*Q4?#F.3P/ZP?O74E.]O[_P"21Z+ZOX*>MKIU\O+X
MR[K39'BVSN5C'6>3                               #S;9;+E>KE;[-
M9K?/=KO=IXJ:U6JFBDGJ:FIGD2*****)'.>][G(UK6HJJJZ)U,9N;6E9M:<(
MC;,SNB&\K*M>T5K$S:9PB(WS/9#;[X>O$M;>*&/6SD'R!Q^"X<F<C@5^/V.9
M8ZF'";?4Q=JQ1Z(K?QC*URI42HJ]C5]DQ419%?PIZN]5[<US)TFEMAIJ[YW>
M.8_ECA''?/##G7T9Z05Y1EQJ]76)U5HV1O\ RXGA_%/&>&Z..-^)\(<@@
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M1L   -^GC+^ GB[[L0?29BL2G4$        .OD\@OQP<K/?O(OSC(1N$/ H
M O3_ &?;XR]S/]V-Y^M6."$LV%E8       05\FGP$\HO=B?Z3"%A@+(V
M&X#PH_9Z;4_E3*?K%5E8E:\$          ""ODT^ GE%[L3_ $F$+# 61L
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M[2$ENJJ$*  .=>+OQ,<=O?K$?K!2 EV-)73
M  AYY!O@>Y6>XN1?FZ0+#KY"-@  !M9\&?P%8_[SY)])C*Q*X4(
M $%?)I\!/*+W8G^DPA88"R-@  !M9\&?P%8_[SY)])C*Q*X4(    #![Y;,F
M?E7D*Y&UBRJ^&V5UIME,SUT;&VUX]04+FHC_ $:OB<Y=.BJJJGI(W"N,*  +
MF/!+9J*Y\[(*VK8KI\=P_(JRV.]7U9WOI+>JKJB_YNJ>G31>OW-45"6;1BL
M           PL^8_[2#D9^B'U#LI&X5CA0 !:]X4OM"]J?R9E/U=JQ"6;@"L
M       (>>0;X'N5GN+D7YND"PZ^0C8   ;6?!G\!6/^\^2?28RL2N%"
M        K(\Q_P!F_P C/T0^OEE"PPL$;   #>;XG?L].-'Y,NGUBN!6)6(A
M           IZ\YGP%9![SXW])D"PQ3$;   #?IXR_@)XN^[$'TF8K$IU!
M         JA\UWV>FZWY4Q;ZQ4@6&'\C8   ;]/&7\!/%WW8@^DS%8E.H(
M      =?)Y!?C@Y6>_>1?G&0C<(>!0 !>G^S[?&7N9_NQO/UJQP0EFPLK
M    ""ODT^ GE%[L3_280L,!9&P   W >%'[/3:G\J93]8JLK$K7@@
M    05\FGP$\HO=B?Z3"%A@+(V   &X#PH_9Z;4_E3*?K%5E8E:\$    !BE
M\XNV$F!<ZL@RF.G6*W[OV"QWZGD1/X-9Z>G7'YVIHFB.[K<CW)Z?71?E(W"G
ML*  )$<2MYW\>N2VRF\OM',H<$R"AJ+^C->]]IF?\SN,;=$7J^DFE:G1?2!V
M)]+54M=2TU;15,=915D;):2KB>V2*6*1J/8]CV*J.:Y%145%T5"NF_<
M       ,+/F/^T@Y&?HA]0[*1N%8X4  6<>'#[2#CG^E_P!0[T$ENF*P
M             %27.3@VF2)=]Y]F+1ID2=]3G&#TS.EP3J^2LHXV)_SCY9(T
M_C/PF^OJC^2?2/JY^1X=#KK?!NI>?E[*VGZ>R>&Z=F[B7UPZ'_U/BYCRZOZF
M^](^;MM6/J[8^;?'Q?>I)5%1514T5.BHOI13E@X3OX$
M     (&\JN4<>%PW#;?;VM27,*ACHLAOT3M4M3'MT6.)S?\ [RJ+U5/XO_E?
M@];+R^,NYR-/XML[E3;G.<Y7.57.<NKG+U554Z[R<1@_@4
M                ?UK7.<C6HKG.71K4ZJJJ!LE\-WA]BV=AQ7EGRAL#9]VZ
MED5?M'MA5-1S,6CD:DD5QKF+JBW%S51T42]*=/67^&T2'A]U@ZN3K)MH=%/Z
M6Z]H^;\,?A[9^;^'?S3Z+=&8T45YAKJ_K;Z4GY.RT_B[(^7^+[NE4XX.3H
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M!4345$]7/-554SZFIJ7NDJ*B1RODDD>JN<YSG*JJJJNJJIUWE(C!^04
M                          -=_AA\0%/BE+BW+_E5BKG9E,L5?LIM'<H$
M1MHCZ207BY02]5JW='4L#T_@4TD<GM5:D7$OK'U<G-FV@T-O@W7O''MK6>SM
MGCNC9CCS%Z)=&XR8KS'7U^/?ETGY>RUH[?ICAOG;AAJ,.,;E6
M               !A_\ -;]H7NM^3,6^KM(26ZJH0H  YUXN_$QQV]^L1^L%
M("78TE=,                          "'GD&^![E9[BY%^;I L.OD(V
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MLMUZLU?#=;/>((:JU72GD9-3U--41I+%+%)&JM>Q[7(YKD71475"L//
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M6661RO<][GJJN<Y5U55])W#RM:Q$80\<-
M    !JZ\+GB#D63&N87*W$$2)$@K]B-IKE$O<KM4FAO=RIY4Z(G1U'"].O\
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M>VM9[>V>&[?NY4]$^C4YTUYCKZ_!&VE)C[W9:T?3],<=\[,,=>IQ)<QP
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M! SN7MCC:C4557355533B4     +./#A]I!QS_2_ZAWH)+=,5@
M            K3YK<(*'=BCN&Y^U-MBMVY]&U\M[L<360PY Q-7N7IHUM6G[
MUZ_QGH=UT<GWGI3U9ORVT:35S,Z>=D3.V:?_ (]W#?'8XU]:NB.7S:EM;H:Q
M751MM6-D9G_Y]D_-NGA*@^KI*J@JJFAKJ:2BK:*1\591RL='+%+&Y6/8]CT1
M6N:J*BHJ:HIS'R\RMZQ:LXQ.V)C=,.!6;E7R[S6T3%HG"8G9,3'"7CFW3
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M'%&R*)B111(C8XVHC6M:U-$1$3T(AP\F<7-6(P?[(H
M          !A_P#-;]H7NM^3,6^KM(26ZJH0H  YUXN_$QQV]^L1^L%("78T
ME=,                          "'GD&^![E9[BY%^;I L.OD(V   &UGP
M9_ 5C_O/DGTF,K$KA0@          05\FGP$\HO=B?Z3"%A@+(V   &UGP9_
M 5C_ +SY)])C*Q*X4(    #^.:US5:Y$<UR:.:O5%10,.?E>X/57$;?RMR'$
M+.Z#8S=Z>IN6W\\4:_-K55N=[6KM#E35&^P<[N@1?3"YJ)JK'Z1N)57!0
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ML       (*^33X">47NQ/])A"PP%D;   #<!X4?L]-J?RIE/UBJRL2M>"
M       !!7R:? 3RB]V)_I,(6& LC8   ;@/"C]GIM3^5,I^L565B5KP0
M   !G5\U_CTJ<_M=;S#V=LZU&7XO2-;O;C5.S62Y6JCC1D5UB:U-5FI(VHR=
M.O="C7)I[->^-1+*6&@    ?0XMEN5X-?*+)L*R:X8?DEL=WV[(;76U-OKJ=
MWW8YZ1\<C%^^CD LQVM\S7/?;.*DHZO<RBW/M=%TBM^4VBEKGN3[DE71?,ZQ
M_P"ZZ=5^^$P3!L/[0WOS3PTS<GV"Q&[U#7,6LEH*R\VUDC$1O>C&U$M<K%54
M=HJN=IJG1=.K%/"]O=OVB'=N99?Q%QOQRW(L:I E7>;G6]LVBZ.=[&*EU;KI
MZJ:+]_[C$\*.N?>=[G'ED4\&,)B.US'HYM/56BPOK*EB*JZ.5V0U-QB<Y-?3
M[)$Z?@^D8KX5:&\/)?D!R K/G>\^\%_W$:R19J:V7&XSOMU-(O174]$Q6TT/
M_P!G&T*X.        LX\.'VD''/]+_J'>@DMTQ6
M  !6WS3X04F\D59N7M=2P6S=*FC5UXM.K8:>_P <;.B*OX+*I$31CUT1_1KU
M3HY/NO2KJU;E<QI=7,VT\[IWS3_&O;'#?'9/&_K1T1ISF)UFBB*ZJ(VQNC,B
M/W7[)W3NGMB@RY6VXV:X5EJN]!-:[I;I'PU]NJ(WPSP2QKVN8]DB(YKD5-%1
M4.9.1GTS:1>DQ:L[8F-L3'=+@3J=-F9.9-,R)K:LX3$QA,3V3#PCJN@
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M(B)HB'#*]YM.,[9ESAI2*Q$1&$0\@RT
M ,/_ )K?M"]UOR9BWU=I"2W55"%  '.O%WXF..WOUB/U@I 2[&DKI@
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MUG<J1^S6HAD5$T3VC7N5&L54)+9N5@     "'GD&^![E9[BY%^;I L.OD(V
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MD')3CKCRU6S5TE=4Y_M_10JK\3J)5U?4TT4:+K;GN756M3^ 5=-/9:=D;B5
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MKE7O=+6U\\CI9I9'+JKGO>JJJK]U3K/(UK$1A#PPT
M            %]?A^\2MWY89)9^0>_EBEMO&+&ZES[/8ITE@GSBNIG*WV$/:
MK7-M\4C=*B9/XQ46*/K[1T?PKJYU7IRK+G2Z6<=3:-L_1$\9_%,;HX;YX1/(
M'HUT@OS?-C6:NN&EK.R/_P!DQPC\,3OGCNCC,;@K9;+;9+;;[-9K?!:+/:((
MJ6U6JEBCIZ:EIJ>-(HHHHHD:UC&-:C6M:B(B)HG0X3YN;:]IM:<9G;,SOF7.
MO*RJTK%:Q$5B,(B-T1V0\XPZ@                               8?\
MS6_:%[K?DS%OJ[2$ENJJ$*  .=>+OQ,<=O?K$?K!2 EV-)73
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M$      AYY!O@>Y6>XN1?FZ0+#KY"-@  !M9\&?P%8_[SY)])C*Q*X4(
M       "LCS'_9O\C/T0^OEE"PPL$;   #>;XG?L].-'Y,NGUBN!6)6(A
M        IZ\YGP%9![SXW])D"PQ3$;   #?IXR_@)XN^[$'TF8K$IU!
M      JA\UWV>FZWY4Q;ZQ4@6&'\C8   ;]/&7\!/%WW8@^DS%8E.H(
M   =?)Y!?C@Y6>_>1?G&0C<(>!0 !>G^S[?&7N9_NQO/UJQP0EFPLK
M ""ODT^ GE%[L3_280L,!9&P   W >%'[/3:G\J93]8JLK$K7@@
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M4]5C6M1$*QBQN^8_[2#D9^B'U#LI&X5CA0 !9QX</M(..?Z7_4.]!);IBL
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M8XC>[=C5DC?%')55E51/BBB:Z=[&(KG*B:N<B??!#&5^J>\A?^&BZ?SICO\
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M9[N8K-A><V>OR":Y8_/-2SR11UE[J:J%ROHY9HU[XWHY-'?+U*S*Q((
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M!'[ 86?,?]I!R,_1#ZAV4C<*QPH  LX\.'VD''/]+_J'>@DMTQ6
M                     !$3FEPMV=YR;.W':C=>W>PJX/:5.!9[31L==,=N
MCF=K:FF<[3N8[1&S0N7ME;T714:YOMODWSEK.2:R,_(G9NM6=UH[)]T[XGUP
M].\[^2-%S[13I]1&W?6T;ZSVQ[XW3'JF.OVYG<+MY>#F[U=M3NY:TDAJ$?4X
M/G5(R1;3D-M1_:E32R/1-'-U1LT+O7C=T75%:YW/?R=YRT?.])&?D3W6K.^L
M]D^Z=TOSP\[>2-;R'63I]1'?6T;K1VQ[XWQ/J1(/;'IX
M                  "Y'Q.^+#(N=>:.W#W'958QQCP2L9'DMWC22"JR:NCT
MD6UV^71.UJ)I\ZG:NL;51K?7<BM^/]5>J&7R/)_*R<+:F\;(X5CZI]T<>.R-
MOVGI%TGS.?Y_YV=C72TG;/&T_37^:>'#;.S>)A>%XGMUB>/8)@F/4F)X=B=)
M#0XWC=#"RGI*.DIV(R.**-B(B(B)_E]*]3@QK-9FZC-MFYMIM>TXS,[YES]T
M6BR=-DURLJL5I6,(B-D1$/ICMG=
M
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MNE32M;I)6T[&JV.55TZHYR.>R-S"XIDA
M
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M\'N+8^],4L.35[W>R]IVI):WVO7NU3LZUB)W??[?E$)9MJ*P
M                   $8>6O$39;FCM+<MHMZ; MPMDKEJ,;R2F5D5VL5R:Q
M6,K*&=S7=DB(NCFJBL>W5KVN:NA[-Y4\VZWDVKC/T\X3QB=UH[)C]IC?#U;S
M?Y.T/.]'.GU-<8WQ,;ZSVQ/;]D[I=?GSEX-;P<$-X*S;3<NC6YX]<UFJ-MMR
M:>%[+9D5L8]&^UB[E=[.>/N:VHIW.5T;E3JYCF/?SX\D>=]'SW1QG9,X6C9:
ML[ZS[XGA/'TXQ'YW^?/(>MY!K9R,^,:SMK:-UH]TQQCAWQ,3,+CW)Z0
M                           "V;Q8^,3,^>FY,>0Y73UF+<:,'JFIN%F\
M:>QEN=0QJ2I:+8^1%1U1(BHLTB(J01KW+ZSHVO\ E/5#J7D\BTW@IA;4WCX:
M]GXK=W9'&>[&8^O=)^EF?Y@U7CS,:Z6D_%;MGZ:]\\9^6._")WQ[>[>X3M1A
M.,[<;<8S28;@V&TD=#C6-4,:14U)31)T:U.JJJJJN>]RJYSE5SE5RJJ\$>8<
MPS]7GVSLZTVO:<9F=\S^WL?H+R[EV1I,BN3DUBF72,(B-T1^WM?9'9N]
M
M
M
M
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M&16*9=(PB(_;?VSOF=LOOCL'D
M
M
M
M                                          ?-4N98E795>,&HLFH*
MO,\?I*2OON*1U4#[A1T5>^6.GGFIVN61D<KH'HQRIHNBZ ?2@
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MK:C/MXLR\XS/NCLB-T1PA^B'(^1Z;ENDIIM/7PY=(PB/?/;,[YGC+E0\6\L
M
M
M
M
M               " 'D(YX83P>VEDODWS?(=W,N9-3[5X ]^OSFI:W1U95MC
M>U[:.G546145%>Y48U45W<TL0QF[7\T>06UG)*7E3;,VFO>ZUVK)JG,JRO59
M*6^TU4K?G%%60Q*QJTSVM:UK&=J1]K%C[%8Q4C6#<7Q%Y=;4<RMJ*#<W;*O]
MC50^SI\VPFHD8MRL-R5G<ZGJ&MT[FNT589D3MD;U314<UM9F$I@@
M  ?E//#30S5-3,VGIZ=KGSSO<C&,8Q.YSG.=HB(B)JJJ!AF\KO,^GY?<CZEF
M&W%:W9O:)E19=MYF.58;B]TJ.KKHU%^2JDC:V-?EACC541RJA&XA5^%  'M;
M%9+MDU[L^-V"@DNM]R"JIZ&RVN%O=-4U=7,V"&)B?*Y[WHU$^ZH'8M<:]F[=
MQ[V#VDV6MJQR1[=V*AM]?5Q-[8ZJX-B22MJ431/X^I?)*OWW%8ES>$
M                             <0;Z[#[5<E-L<DVAWFQ&FS/!\GB5E7;
MYVI[6GG1CFQU5+*GKP5,*N58Y6*CFKZ%TU0\OR/GNJY;J:ZC3VFMZ_;W3VQ/
M&)>&Y_R#2<STMM/J:Q?+MP[.^)X3'"88"/(WXVMU^ 6Y4M)<(*K,=C<HJ'_[
M,=VV4ZI!.UW=(V@N"Q)V05\;&KJSHDK45\?3N:SGGT[ZC:7GVFQC"N?6/BI[
MX[:S]FZ>&/YZ]2NF6K\O:K"<;Y%I^"^'V6[+1]N^..%;1]&?,@
M               3Y\>W +<WGYO)#@N+.DQG;O&_956ZNYSZ=\M+9Z![]$BC
MZ(V2LJ.UR4\*N371SET8QRIZ)Y_\^:;D.C_-O\69;92O&9]T1QGU;YA]!Z<]
M/=5YAUOY67\.77;>^&RL>^T\(]>Z)=@OQZX];4<7-J,8V9V9QB/&,*QB/2.-
M-'U==5O1/;5M;-HBS5,RIK)(OWD1$:C6IP$\P>8-5S356U&HMXKV]D1PB(X1
M'"/>_1/RYY<TG*M)73::OAI7VS/&9GC,\9]SFL\*\X
M
M
M
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MCHJO**MKV6Z-O>FBK3(U]4JM75CV1:_A($F6RTK
M                 XSWAV>VWW\VWRK:3=O%:;,\!S.F=37VQ5+5T<FJ.9+$
M]JH^*:)Z(^*5BH]CT1S51413R7*.;ZG0:FN?D6FN96<8F/VVQ/&-TP\7SGDV
MFYAIK:?45B^7>,)B?VV3&^)C;$[88'/)=XOMT. 6;I=Z9\V=<><OK)8]O-RV
MQJLM*]W=*RVW=(V-9#6-8BJUS?X.=J*]FBH^./G?TWZFZ7GV1X9^#45CXJ]O
MXJ]L?;&Z>$S^?75#I7JO+V?XH^/36GX;=GX;=EOLMOCC$59GT]\H
M               $U>"O!O=OG=O-;]M-NZ)]MQ>UO@J=T-R)HG.M^/6I\G:Z
M5Z]$DJ)4:YM-3HJ.D<B_@L:][/3//'G?2<BT<YV;.-IV5KQM/^$<9X>G")]X
M\@^0]9S_ %L9&3&%(VWMPK'OF>$<9[HF8["GC/QGVBXE;18YLOLOCC;#BEA;
MWU=6_MDK[K7R-:V>OKYVM:LU3,K4[G:(B(B,8C6-:U. 'F3S)J^;:NVHU%L;
MS[(CA$1PB/\ .=N,OT7\K^5]'R?1UTVFKX:5]LSQF9XS/^481$0Y]/ O80
M
M
M
M
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M75E4NK6KVZM;'$CDU;$QC5U5-2L2E,$
M         #X'=':[ -Z< RG:W=+%J7-,"S2E?1Y'CE8Q7PSPO5'(J*U4<R1C
MD1\<C%1['HCFJCD14[_E?--1HM17/R+37,K.,3'[>V-TQLEX_FO*M/KM/;(S
MZQ?+O&$Q/[;^R=\3MA@V\HWBNSK@3E[,OQ%]9G?&G+:CV6)YS*QKZNSU<B*Y
M+;=EA:UC9>B^QF1$9,U.B(]'-3G1TQZHY'/<G\O,PIJ:QMKPF/JKW=L;X]&U
MP ZK=)M1Y?SOS,O&^EM.RW&L_3;O[)W3Z<85%GUE\>
M   2ZX6\+=XN<F\5NVHVHMWL*2#V=3GN>U,;UM>.VM7]KJFI<W3N>[14AA1>
MZ5W1-$1SF^I><O.6CY)HYS\^=NZM8WVGLCWSNB/5#W'R1Y(UO/M;&GT\;-]K
M3NK';/NC?,^N8["KB7Q1VFX:[+XWLMM%:$I;7:6-FR+(Y61_C&_75\;6U%PK
MI&(G?+*K4T3\%C4:QB(QJ(G #S7YJU?.-9;49\XS.Z.%8X1'='VSMG:_1?RA
MY1T?)-#73:>,(C?/&T\;3WS]D;(V0DN>MO:
M
M
M
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MGSAWI8W2)-/X17F9E=F5D
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MN
M
M
M
M                       A?S2X,;,\W,!;C.X=(ZR9E9(YOZ@;GT4;'7.S
M3RZ.5-'*U)Z9[FI[6!ZHCDZM<Q_:]I8EBTY=\'=^N&&8+8-U,<6IQ>XRO;A^
MYE V2:QW>-JJJ)',J(L4Z(FKZ>5&R-]*(K%:Y8U$H>!0             'T6
M)8CE.>Y+9<-PG'JS*\LR.=E+8L=M]/+55E74/]#(HH4<YR]->B=$Z^@#7AXR
M?$E9^-C[-OGR%I*7)M^FHD^+XLU\=5;,2[V(J/[FHK)[@W5465JJR/\ S>JI
M[0,S*\PK(                                          !Z+)\8QS-
M<<OF(9?8Z7)L6R:EGH<AQZN@CJ:.MHZF-8I89HI4<U['M<J*BIHJ'7TVIS,G
M,C,RYFMJSC$QLF)CC#M]5I<K/RIR\R(M2T83$[8F)WQ,,-/E@\0^6<.+Y>=[
M-DK=597Q:N]0U\R=SZFOPNHJI>UM)6JJJ^2C5ZHVGJEUTU2.5>_M?+S<Z5]6
MLKG%(TVIF*ZJ(]$7PXQW]M?7&S&(X']7.CF=R7,G4Z6)MI)GTS29X3VU[+>J
M=N$S1N?;7P<                2!XP\9=U^7&\F*[)[/6)UVR7(I6NN%R>U
MZ4%GMK)&MJ+C7RL:[V5- CD5RZ*KE5&,1SW-:O@/,WF72\IT=M3J)PK7AQF>
M$1VS/^<[(F7L7E7ROK.<:VNFTU<;6WSPK'&TSPB/\HQF8AV%'!G@SL_P0V?I
M-M-M*1+ID5T2&HW*W*J(6,N>17-C%;[67M5WLX(^YS:>G:Y6QM5>KGN>]_ '
MSOYWU?/=7.=G3A6-E:QNK'OF>,\?1A$?HOY#\AZ+D&BC(R(QM.VUIWVGW1'"
M.'?,S,S2/3'NX
M
M
M
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M_<KPK'OF>,^Z(A^BO3SI]I/+^BC*RHQS+83>_&T^ZL<(X>F9E.\]&>_@
M
M
M
M
M                      'SF68=B6>V&OQ7.<7M^98S=&]MRQZZ45/<**H;
M]R2"J8]CM/DU0"HW?CP=<.-UY*V[;?0W787(ZE7/:ZQU'SRSNE=\K[=<UE[6
MI\C*>6%HP7Q*C=VO 1RJQ"2IJ=JLXQG>"UQJOS:F=--CMVD^^M/7I+2M_P"E
MJ3!KQ*]L_P#'=SAVSDG9E/&#+GQTSE;45EIMC\AI6::^LL^/K6Q=O3\+NT^_
MU0&*+.0X1FF(R/BRO$+IC$L;D9)%<;?5T3FN=KHBI4QL5%71>@5\N!_MC'RO
M9'&Q9))%1L<;457.<JZ(B(GI50.5<8V&WRS>1D.&;,99ETTB]L<5KQV\5[G.
M[D;HB4E/(JKJJ)^Z#%+K;KQ1<^]R9:7\7\>;GB]#.J>VN615%OQ]L#=53N?#
M=)XJA>OR,B<[Y=- F*R;9G]GJW"N4E)7[^[Z6O%:/5'5..8M1U%VJWL73U%K
M+DVBBA>GRJD,J?<U](P3Q+H^.WC X9\:9J*[8AM7%F&94#FOIL]RE[+Y<XY&
M(G;)"V:-E-3O3T]\$$;NOI*F*P,(
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M?9P?HCTTZ<:;R[H_!7"V=;;>_;/9'X8X1ZYWK%#YZ^D
M
M
M
M
M                 'SU1B.*5<\M55XQ;ZJIG<KYZB2BIGR/<JZJKG.8JJJ_
M=4#V-NM-JM$3X+3;*>UPRN[Y(:>&.!KG:(FJI$C45=$]('L
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MFM^*?9$;(XS/Z%]+^F&F\NZ7A?47CX[?RU[*Q[9G;/"(LZ/FCZF
M
M
M
M
M
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M'2+HC&,X.]1.IFKY]G83\&16?AI[[=L_9'#C,\^.FG2S1^7LC&/CU%H^*_\
M+7LK]L[YX1%GA\S?4P
M
M
M
M
M                                                       !7YS)
M\97$[F[33W'=/!UL6Y#84AMN[]@=';L@B1C>V-L\G8^*KC;IHUE3')VIKV*U
M5U/?O)_4KFO)9PR+XY?&EMM?5QCU3'?B^=^=>EW*.>QCGT\.;PO79;U\)CTQ
M/=@S)<C_ -G;Y9[;5-;=-@<FLW(;%VJ]U+;/;0XWD3(TU?H^GNDWS1^B=-65
M?<Y?0Q/0<E?+O]P?*M3$5U5;9-NW[U?;$8^VOK<7/,O]M_.-+,VTEJY].S[M
MO9,^'V6]2G[<WB)RFV:JJBEW1X\9EA*4[NU:^NQVZ,HI%[_9ZQ5;8702M5W1
M',>J*OH4^N<M\V\KUD8Y.=2_HM&/LQQA\:YIY.YMHIPS\C,IWS6</;AA/JE'
M4]A>MO:6:QWO(J^&U8_9ZJ^W2H5$@MM'3S550]7.1B(V.!KG+JKD3HGI4Z6=
MGTRZ^*\Q$=L['5R<B^;;PTB;3V1&*<VS7BZY];ZU%,W"N,636VVU"M5,BR*D
M3%;=[)5365D^1.HTF:FO^9[U7JB(J]#TCG'4[D.AC]344F>RL^*?97'#UX/?
M.2]*?,.OG]+3WB.VT>"/;;#'U8KU>+'[-O;Z26W9+S#W>2[+&K))-K<+62*G
M<J*UZ,JKQ<(6R.:J:MDC@IV+_P ";T*?#_-']QEIB:<ORL/Q7]U8GV3,SWP^
M]^4_[9JUF+\QS<?P4W>NTQCZ8B([K-+&SNR&T7'W"J';K97;RU[;89;U[HK)
M:Z9L#9)5:C733R+K)/,Y$3NEE<Y[OE<IQOYOSO5\PSIS=1>;WGC,_9'9'=&Q
MR>Y+R+1\NR(R=-2,ND<(C[9XS/?.URH>+>6
M
M
M
M
M
M                  0.Y _^T6J_]$I?_F*>]<@_^OZY?/\ S'_]GU0D'Q^_
M]G5-_P"EU7_SD/7^?_\ V/5#V/R[_P#6CTRYN/"O.@
M
M
M
M
E                                             !__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
